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Abstract 
Spirometry and plethysmography provide gold standard measurements of obstructive 
lung disease, although these are global measurements of lung function made at the 
mouth, of a highly regionally heterogeneous disease.  Hyperpolarized 129Xe magnetic 
resonance imaging (MRI) is a non-invasive, non-radiation-based imaging tool for 
visualizing regional lung structure and function.  However, the reproducibility of 129Xe 
MRI measurements has not yet been studied or determined.  Hence, in this thesis, we 
evaluated the reproducibility of 129Xe MRI using quantitative measurements such as 
ventilation defect percent (VDP).  We showed that 129Xe VDP had high intra-observer 
and inter-observer reproducibility for repeated scans acquired on the same-day and after 
1-week and its reproducibility was comparable to that of 3He VDP.  129Xe VDP showed 
strong and significant correlations with pulmonary function tests.  These results 
suggested that 129Xe VDP is reproducible over short periods of time and can be a reliable 
measurement to study pulmonary function in imaging studies. 
 
Keywords: Hyperpolarized, 129Xe, 3He, magnetic resonance imaging, chronic obstructive 
pulmonary disease, reproducibility, functional lung imaging, ventilation defects 
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1 CHAPTER 1: INTRODUCTION 
During the last two decades, hyperpolarized noble gas magnetic resonance 
imaging (MRI) has emerged as an important tool to study pulmonary diseases like 
chronic obstructive pulmonary disease (COPD) and asthma.  Understanding the anatomy 
of the lung and the physiological changes that take place after the onset of disease is 
critical for understanding the mechanism of disease progression and improvements after 
therapy as well as the implementation of new diagnostic tools.  The objective of Chapter 
1 is to provide a motivation for the work presented in the following chapters as well as 
provide an overview of pulmonary anatomy, pathology of obstructive lung disease, the 
diagnostic tools and the different imaging modalities currently used to evaluate 
pulmonary disease.   
1.1 Burden of Pulmonary Disease  
According to the World Health Organizations’ global burden of disease 2004 
update, respiratory diseases were responsible for 6.8% of all male and 6.9% of all female 
deaths worldwide.6  Chronic obstructive pulmonary disease (COPD) was the 4th leading 
cause of death worldwide, and accounted for three million or 5.1% of all deaths 
worldwide while asthma was responsible for another 0.287 million or 0.5% of all deaths 
worldwide.6  It is predicted that by 2030, COPD will be the 3rd leading cause worldwide 
accounting for 8.6% of all deaths as shown in Table 1.1.7  It was estimated that the 
prevalence of COPD was 63.6 million and asthma 234.9 million worldwide in 2004.6  
Asthma was the leading chronic disease in children in industrialized countries.8  COPD 
and asthma were the 10th and 13th leading causes of moderate and severe disability in 
2004 responsible for 26.6 million and 19.4 million disabilities worldwide respectively.6  
In Canada, respiratory diseases were the 3rd leading cause of death just below 
cardiovascular disease and cancer in 2005.1  As shown in Figure 1.1, respiratory diseases 
were responsible for 8.7% of all male deaths  and 8.6%  of all female deaths in Canada 
with COPD alone accounting for 4.5% and 4% of deaths respectively.1  The economic 
burden of respiratory diseases is enormous, with COPD and asthma accounting for 3% 
and 1% of all hospitalizations in Canada in 2004-05.1  As shown in Figure 1.2, 
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respiratory diseases were ranked 8th in terms of the total healthcare costs in Canada 
accounting for just over 5.6 billion dollars in 2000.1  In 2010, the cost rose to 
approximately 12 billion dollars, and in the best case scenario, the number is expected to 
rise to just over 24 billion dollars in 2030.9  Asthma was the number one cause for 
emergency room visits in Canada in 1994.8  There were 3.1 million people suffering from 
asthma and just over 1.65 million from COPD in Canada in 2010.9   
 
Table 1.1 Leading causes of death worldwide 2004 and predicted values in 2030. 
Adapted from World Health Organization.  The global burden of disease: 2004 update6 
and World Health Organization.  World Health Statistics7 
 
   
2004     2030 
Disease Deaths 
(%) 
Rank Rank Deaths 
(%) 
Disease 
Ischaemic heart 
disease 12.2 1 1 14.2 
Ischaemic heart 
disease 
Cerebrovascular  
disease 
9.7 2 2 12.1 
Cerebrovascular 
disease 
Lower Respiratory 
Tract infections 7.1 3 3 8.6 COPD 
COPD 5.1 4 4 3.8 Lower Respiratory Tract infections 
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Figure 1.1 Proportion of all deaths for men (A) and women (B) in Canada in 2005 
Reproduced with permission from Life and Breath: Respiratory Disease in Canada1 
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Figure 1.2 Total economic burden of respiratory diseases in Canada in 2000 
Reproduced with permission from Life and Breath: Respiratory Disease in Canada1 
Note: Respiratory infections include lower and upper respiratory tract infections, otitis 
media and tuberculosis. Respiratory disease includes asthma, COPD and other diseases of 
the respiratory system (excluding lower and upper respiratory tract infections, lung 
cancer and tuberculosis), Total Respiratory is a sum of Respiratory infections and 
Respiratory disease (excludes lung cancer) 
Recent studies have shown that the prevalence of COPD is actually much greater 
than previously believed, with a reported 9-10% of adults aged 40 years or higher having 
COPD worldwide.10,11  Studies have also shown that of these individuals who were 
determined to have COPD, only 19% were previously diagnosed and treated.12  These 
studies suggest that COPD is highly under-diagnosed and the majority of patients do not 
have a diagnosis or a treatment plan for the disease.  Reports from 1979 in Canada 
showed 2.3% of the population suffered from asthma, whereas in 2004, this number 
jumped to 8.4% of the population.8  These results suggest that there is an immediate need 
to develop new imaging tools for early detection and diagnosis of these respiratory 
diseases in the future.   
In the following sections, I will be describing the anatomy of the lung, the nature 
of obstructive lung disease as well as the gold standard and imaging modalities currently 
used for pulmonary disease diagnosis. 
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1.2 Lung Structure and Function 
Human cells obtain most of their cellular energy in the form of adenosine 
triphosphate (ATP) from glucose through a process called as cellular respiration.13,14  
Oxygen is required by the cells for respiration and carbon dioxide is formed as a 
byproduct.13,14  Hence there is a need for transfer of oxygen from the external 
environment into the body and carbon dioxide from the body to the external environment.  
The main organ responsible for this gas exchange with the external environment is the 
lung and the respiratory system assists in this process.  The respiratory system consists of 
the oral and nasal cavities, the paranasal sinuses, the pharynx, the larynx, the trachea, the 
bronchi and their smaller branches, and the lungs, which contain the gas exchange 
chambers, called the alveoli.13  Functionally the respiratory structures are divided into 
two zones- the conducting and the respiratory zones as shown in Figure 1.3.2  The 
conducting zone extends from the top of the trachea to the beginning of the respiratory 
bronchioles; and has no capacity for gas exchange with the blood as these airways are not 
lined with alveoli. The respiratory zone extends from the respiratory bronchioles down; it 
contains alveoli and is the region of the lungs responsible for gas exchange with the 
blood.14 
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Figure 1.3 Schematic of the human airway tree by generation (Image is not to scale) 
Image adapted from West JB, Respiratory Physiology; The Essentials2 
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1.2.1 The Conducting Zone 
The organs that make up the conducting zone filter, humidify and warm the air 
passing from the external environment to the lungs.  As shown in Figure 1.3, the airways 
consist of a series of branching tubes that become shorter, narrower and more numerous 
through the generations of airways (deeper in the lung).  The airways have about 23 
generations of dichotomous branching.15  Generation number zero, or the trachea, divides 
into the right and left main bronchi, which in turn divide into lobar, followed by 
segmental bronchi.2  This process continues until the terminal bronchioles, which are the 
smallest airways without alveoli, and the last generation of airways included in the 
conducting zone.2  The airways of conducting zone do not partake in gas exchange as 
these airways are not lined with alveoli, and hence the volume of gas present in the 
conducting zone is called the anatomical dead space which is approximately 150 ml in a 
healthy adult.2  
The flexible trachea, or windpipe, descends through the larynx, through the neck 
and into the mediastinum.13  A study by Kamel et. al using computed tomography (CT) 
scans showed that the average tracheal length in males was 105mm while that in females 
was 98mm with males having an average tracheal volume of 36 cm3 and females 24 
cm3.16  The wall of the trachea contains 16-20 C-shaped rings of hyaline cartilage 
connected by membranes of fibro-elastic connective tissue, enabling the trachea to be 
flexible enough to permit bending and elongation during inhalation and exhalation, but 
preventing it from collapsing due to the changes in pressure during breathing.13  All the 
air moving in and out of the lungs must pass through the trachea which divides into 
generation one of the airways or the two main bronchi. 
The right and left main bronchi originate from the trachea and are also called the 
primary bronchi.  The left and the right main bronchi are responsible for transport of gas 
from the trachea to their respective lungs.  The main bronchi further divides into 
generation two of the airway tree or the lobar bronchi.  The human lungs are divided into 
several lobes- three on the right and two on the left.13  There is one lobar bronchus 
supplying each lobe, hence a total of five lobar bronchi exist.  The lobar bronchi further 
divide into generation three or the segmental bronchi, which in turn repeatedly divide into 
smaller bronchi till about 23 generations.  The generations smaller than 1mm in diameter 
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are called bronchioles (“little bronchi”) and the smallest of the bronchioles, known as the 
terminal bronchioles, are less than 0.5mm in diameter.13  The terminal bronchioles are the 
last generation of airways of the conducting zone and hence the last generation of airways 
that do not participate in gas exchange and are found around generation 16.2  They further 
divide into the respiratory bronchioles which are the first respiratory zone structures.   
1.2.2 Respiratory Zone 
The respiratory zone is the last part of the airway tree, distinguished from the 
conducting zone by the fact that the walls of the airways are lined by the air-exchange 
chambers called the alveoli.  The first generation of airways in the respiratory zone, 
called the respiratory bronchioles (generations 17-19 of the airway tree) have scattered 
alveoli protruding from their surface.13  The respiratory bronchioles lead into the next 
generation of airways known as the alveolar ducts.  The alveolar ducts are straight ducts 
whose walls are almost entirely covered with alveoli.13  The alveolar ducts lead into 
terminal clusters of alveoli called alveolar sacs.13  The alveolar sacs are a group of 
alveoli.  The opening from an alveolar duct into an alveolar sac is called the atrium or 
“entrance chamber”.13  The alveoli are tiny hollow sacs whose openings are continuous 
with the lumens of the airways.14  The alveoli are the location where the actual gas 
exchange occurs.  A study by Ochs et al.17 estimated that the mean alveolar number in 
human lungs was 480 million and was closely related to total lung volume with larger 
lungs having significantly more alveoli.  The study also reported that the mean size of an 
alveoli was constant (4.2 x 106 µm3) irrespective of the size of the lungs.  In this part of 
the respiratory zone, the alveolar walls contain capillaries and a very small interstitial 
space.14  In many places, this interstitial space is completely absent.14  Hence, the blood 
within the alveolar-wall capillary is separated from the air within the alveolus by an 
extremely thin barrier (0.2 µm, compared with the 7µm diameter of an average red blood 
cell).14  For a healthy individual, the total surface area of the alveoli in contact with the 
capillaries is roughly the size of a tennis court.14  The large surface area coupled with the 
thinness of the barrier allow for the rapid exchange of large quantities of oxygen and 
carbon dioxide by diffusion.  The rate of diffusion of gases across the membrane is 
described by Fick’s law for diffusion, as shown in equation (1): 
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PPDADiffusion )( 21 −⋅⋅= (1) 
where, A is the surface area of the lung for diffusion, D is the diffusion coefficient of gas, 
P1-P2 is the partial pressure difference of the gas across the alveolar capillary membrane, 
and T is the thickness across the alveolar capillary membrane.  The gas diffusion rate is 
therefore directly proportional to the surface area of the lung, the diffusion coefficient of 
the gas and the partial pressure difference, and inversely proportional to the thickness 
across the lung membrane.  As the total surface area of all alveoli in an average pair of 
lungs is 140 square meters13, and the thickness of the interstitial space is extremely small 
(0.2 µm)14, the efficiency of gas exchange is high.  The oxygen flows from an area of 
high partial pressure (inside the alveoli) to an area of low oxygen partial pressure 
(pulmonary capillaries), hence the oxygen is transported from the external environment to 
the blood through the respiratory system.   
1.3 Obstructive Lung Disease 
Obstructive lung disease (OLD) includes several conditions including obstructive 
chronic bronchitis, emphysema and asthma18 and is characterized by airway obstruction, 
inflamed and easily collapsible airways, obstruction to airflow and problems exhaling.  
Of these, COPD is divided into chronic bronchitis and obstructive emphysema, or a 
combination of these occurring together.18  Asthma is an inflammatory disease of the 
airways, although there is a lot of controversy regarding the best definition of asthma as it 
is a clinically complex condition.19,20  
1.3.1 Chronic Obstructive Pulmonary Disease 
COPD is a category of obstructive lung disease, found mainly in smokers, 
characterized by difficulty in moving air into and out of the lungs, or obstruction to the 
flow of air.  In the Global Initiative for chronic obstructive pulmonary disease guidelines, 
COPD is defined as “A disease state characterized by progressive development of airflow 
limitation that is not fully reversible.  The airflow limitation is usually progressive and 
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usually results from an abnormal response of the lungs to noxious particles or gases.”21  
Cigarette smoking, while not the only factor leading to COPD, is the main source of the 
inhaled noxious particles that leads to its development.  Both environmental and genetic 
factors also contribute to the development of COPD.  Although only 10-15% of smokers 
actually go on to develop obstructive lung disease,22 active, sustained cigarette smoking 
contributes to the origin of COPD in more than 90% of the subjects.23  Genetic disorders 
such as alpha-1 antitrypsin deficiency have been shown to cause emphysema.24,25  
Although not all smokers develop airflow limitation, studies have shown that cigarette 
smoking is associated with inflammation in both the large and small airways,26,27 as well 
as the lung parenchyma28 in smokers with normal forced expiratory volume in one 
second (FEV1), which is a standard measure for diagnosis of airflow limitation and will 
be explained in detail in the next part of this chapter.  The disease that occurs within the 
airways is called chronic bronchitis, and that which occurs in the lung parenchyma is 
called emphysema, which are independent diseases that may manifest together or in 
isolation.  However, the same agents that cause chronic bronchitis- mainly smoking- also 
cause emphysema, which is why these two diseases frequently occur together. 
Chronic bronchitis is one of the conditions associated with COPD and is 
characterized by excessive mucus production in the bronchi and chronic inflammatory 
changes in the small airways.14  So significant is cigarette smoking in the development of 
chronic bronchitis that this disease would be an insignificant health problem if cigarettes 
were unavailable.  Inhaled irritants (example from cigarette smoking) are responsible for 
prolonged secretions of excess mucus by the mucosa of the lower respiratory passages, 
leading to inflammation and fibrosis (formation of scar tissue) of this mucosa.  This 
causes an obstruction in the airways because of an accumulation of mucus in the airways 
and thickening of the inflamed airways.14  The obstruction and inflammation severely 
impair ventilation and gas exchange.  Figure 1.4 shows a normal airway with no 
inflammation or over-secretion of mucus in the lumen of the airway, as well as an airway 
inflamed due to chronic bronchitis, with excessive secretion of mucus causing a decrease 
in the diameter of the airway leading to difficulty in ventilation.  Infections also 
frequently occur in these patients because bacteria and viruses thrive in the stagnant pools 
of mucus.  Coughing is persistent and productive in these patients.  Patients with chronic 
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bronchitis are sometimes called “blue bloaters” because lowered blood oxygenation often 
results in cyanosis (bluish discoloration of the skin) and other symptoms of right heart 
failure.  However, the degree of dyspnea in patients suffering from chronic bronchitis 
alone is usually moderate compared to patients suffering from emphysema alone.13  
From the trachea to the alveolar sacs, as the airway generations increase, the 
number of airways increases rapidly due to the dichotomous branching pattern.15  As the 
total number of airways increases, although they become narrower at each generation, the 
total cross-sectional area at each generation increases.  Although it would be expected 
that the resisitance to the flow of air would increase as the radius of the individual 
airways decreases according to Poiseuille’s equation (resistance of a single tube is 
inversely proportional to the 4th power of the radius of the tube), this is not observed 
because the number of airways and their total cross-section area increases rapidly.  Since 
all the airways are arranged in parallel and the resistance of parallel circuits is added as 
reciprocals, small airways (<2 mm in diameter) have a very small resistance to the flow 
of air.  This fact was confirmed by Hogg et. al.29 who showed that in healthy subjects, the 
small airways contributed very little to the total airway resistance.  They also reported 
that in subjects with mild and severe emphysema, there was an increase in the resistance 
of the small airways (<2mm in diameter) with no increase in the total lung resisitance.  It 
was shown that the elevated resistance was due to mucus plugging and narrowing and 
obliteration of the small airways.  They defined this condition as “small airways disease” 
and found that while this condition affected ventilation distribution and gas exchange, it 
did not change the results of the pulmonary function tests designed to diagnose 
obstruction in the airways.  By the time the total airway resistance elevated to a to a level 
recogized by the pulmonary function tests, the obstruction would be much more severe 
that generally thought.  A more recent study by Hogg et.  al.  showed that progression of 
COPD from Global initiative for chronic Obstructive Lung Disease (GOLD) stage 0 
(explained in the next part of the chapter) to GOLD stage 4 was most strongly correlated 
with thickening of the airway wall caused by a repair or remodelling process.4  The 
degree to which the lumen was filled with mucus and the extent of inflammatory 
response was more weakly assocated with disease progression.  Figure 1.5.A shows a 
normal healthy small airway, Figure 1.5.B  shows a small airway partially filled with 
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mucus, Figure 1.5.C shows an airway with an active inflammatory process, where the 
exudate extends into the lumen, Figure 1.5.D shows an airway that has been narrowed by 
secretion of mucus in the peribronchiolar space.   
Emphysema is characterized by a permanent irreversible enlargement of the 
alveoli, caused by the deterioration of the alveolar walls13 and by the atrophy and 
collapse of lower airways- those from the terminal bronchioles to the lower generations.14  
The disease is associated with chronic inflammation and increased activity of lung 
macrophages, whose lysosomal enzymes are responsible for destroying the alveolar walls 
and breaking down elastin.13  Cigratte smoking is the single most important factor in this 
process as it stimulates the release of proteolytic enzymes and destroys other enzymes 
that usually protect the lung against these proteolytic enzymes.14  Figure 1.5.E shows 
normal lung parenchyma in a healthy non-smoker, Figure 1.5.F shows moderate 
emphysema and Figure 1.5 .G shows severe tissue destruction in severe emphysema.  As 
can be observed from Figures 1.5.E-G, as a result of alveolar-wall loss, adjacent alveoli 
fuse to form fewer but larger alveoli thus reducing the total surface area available for 
diffusion and hence for gas exchange.14  Morever, since the tissue destruction is not 
consistent throughout the lungs, some areas may receive little amount of air and sufficient 
amount of blood supply while others show the opposite pattern leading to ventilation-
perfusion inequality.  Chronic inflammation also leads to fibrosis and the lungs become 
progressively less elastic, making expiration difficult and exhausing.13  In these patients, 
the bronchioles open during inspiration but collapse during expiration leading to a 
condition know as “gas trapping” where huge amounts of air get trapped in the alveoli 
leading to a “barrel chest” apperance due to enlargement of the lungs.  Damage to the 
lung capillaries increases the resistance in the pulmonary vascular circuit, forcing the 
heart’s right ventricle to enlarge through overwork.13  Emphysema is usually divided into 
two distinct forms: centrilobar and panlobar.24  Centrilobar emphysema is mainly a 
disease of the upper lobes and the apices within the upper and lower lobes.24  In contrast, 
panlobar emphysema shows a more homogeneous pattern and is mainly observed in the 
lower lobes.  Studies have shown that there is a realtionship between smoking and 
centrilobular emphysema, but not with panlobar emphysema, which may be associated 
with genetic disorders such as alpha-1 antitrypsin deficiency.24,30,31 
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Figure 1.4 Schematic of the human airways and alveoli in healthy volunteers and subjects 
with COPD.   
The airways of the COPD subject on the right shows inflammation and mucus plugging 
and the alveoli show extensive emphysema 
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Figure 1.5 Small Airways Disease and Emphysema in COPD 
(A) A healthy airway with unobstructed lumen (B) An airway with lumen partially filled 
with mucus (C) Acutely inflamed airway with lumen filled with an exudates of mucus 
and epithelial cells (D) An airways with severe inflammation and the lumen has been 
almost completely obstructed by deposition in the peribronchiolar space (E) Histological 
slide from a healthy subject showing lack of emphysema (F) Moderate degree of 
emphysema (G) Severe emphysema sample 
Images reproduced with permission from Hogg et al.4 and Woods et al.5 
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1.3.2 Asthma 
Asthma is predominantly a disease of the airways, characterized by sporadic 
episodes of strong airway smooth muscle contractions leading to an increase in airway 
resistance.  The causes of asthma vary between individuals and include allergies, viral 
infections and sensitivity to environmental factors.14  The basic defect in asthma is 
chronic inflammation of the airways which makes the airway smooth muscles hyper-
responsive and causes them to contract strongly.  The trigger for this hyper-
responsiveness can be a variety of factors including exercise, exposure to cigarette 
smoke, pollutants, viruses, allergens and a variety of other substances.14  An asthma 
attack starts with an early phase, in which mast cells stimulate both contraction of the 
bronchial smooth musculature (broncho-constriction) and secretion of mucus in these 
airways.13  Within a few hours, a late phase develops as eosinophils, neutrophils, a certain 
type of helper T lymphocytes and basophils accumulate in the bronchi and bronchioles, 
where these leukocytes secrete additional inflammatory chemicals that damage the 
bronchial mucosa and further increase broncho-constriction and secretion of mucus.13  
Until recently, it was considered that broncho-constriction was the primary symptom of 
asthma and quick relief is still provided by drugs that either inhibit smooth-muscle 
contraction (bronchodilators) or inhibit the parasympathetic stimulation of such 
contraction (anticholinesterases).  Recently it has been discovered that asthma is 
primarily an inflammatory disease and new treatments using anti-inflammatory drugs 
(gluco-corticoids and nonsteroidal anti-inflammatory agents) have been developed.13  
These drugs allow much better long term management of disease, leading to fewer 
attacks and less damage to the airways.  Functionally, asthma can be defined as airway 
hyper-responsiveness (AHR) leading to areas of airway inflammation and airway 
obstruction (partial or complete).  It might be due to abnormal functioning of the airway 
smooth muscle (ASM) or an excess of ASM cells.  A study by Dunnill and colleagues 
showed that the percentage of smooth muscle in the segmental bronchial wall was 11.9% 
± 3.36% in severe asthma compared to only 4.6% ± 2.2% in healthy controls.32    
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1.4 Established Methods for diagnosis of Obstructive Lung Disease   
Currently, the pulmonary function tests provide gold standard measurements of 
lung function in obstructive lung disease.  These are used by physicians for diagnosis of 
various pulmonary conditions as well as in research studies.  They are used to measure 
lung volumes, bronchial obstruction, gas exchange and lung compliance.33  Pulmonary 
function tests are able to identify abnormalities of lung function and can also be used to 
rule out the possibility of some respiratory disorders such as COPD.  These tests are 
routinely used in the diagnosis of asthma and COPD.  Spirometry is the most widely used 
of these tests.34 
1.4.1 Spirometry 
Spirometry is used to measure static lung volumes at rest-slow (inspiratory or 
expiratory) vital capacity (sVC), forced vital capacity (FVC) and dynamic volumes- 
FEV1.33  The test to measure FEV1 involves measuring airflow and lung volumes during 
a forced expiratory maneuver from full inspiration.  As shown in Figure 1.6.A a hand-
held EasyOne spirometer (ndd Medizintechnik AG, Zurich, CH) is used for this test.  The 
test begins with the subject putting the spirometer in their mouth and making a tight seal 
around it with their lips to ensure that there is no leakage of air.  They are then instructed 
to take a couple of normal (tidal) breaths after which they have to inspire fully.  
Following this they are instructed to exhale as fast as possible and keep going until there 
is no airflow detected by the spirometer.  The volume of gas exhaled by the subject in the 
first second of the forced maneuver is known as the FEV1 and the amount of gas exhaled 
during the entire maneuver is known as FVC as shown in Figure 1.6.B.   
The American Thoracic Society’s guidelines for individual spirograms to be 
acceptable are if “they are free from artifacts- cough during first round of exhalation, 
glottis closure that influences the measurement, early termination or cut-off, effort that is 
not maximally throughout, leakage of air, obstructed mouthpiece, if they have a good 
start: extrapolated volume <5% of FVC or 0.15 L, whichever is greater and show 
satisfactory exhalation: duration >= 6 s or a plateau in the volume-time curve or if the 
subject cannot or should not continue to exhale”.35  After three acceptable spirograms 
have been obtained the following conditions have to be met- “the two largest values of 
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FVC must be within 0.150 L of each other and the two largest values of FEV1 must be 
within 0.150 L of each other”.35  If both the criteria are met, the testing may be 
concluded, otherwise testing has to be continued until the conditions are met with a 
maximum of eight tests performed.35  Although the equipment required to perform 
spirometry is simple and robust, the proper performance of the breathing maneuvers and 
full cooperation of the patient is critical for getting accurate results.  The consistency of 
the spirometer and the technician conducting the test is essential because large variations 
can be introduced in the results otherwise.  The measurements obtained are highly patient 
effort dependent and hence the reproducibility of the results might not always be high.  
These pulmonary function tests (PFT) are also unable to give any regional information 
about the disease and are insensitive to early pulmonary changes after the onset of 
disease.  
The spirometric measurements of FEV1 and FVC are used to diagnose diseases 
like COPD and asthma.  The ratio of FEV1/FVC is used to measure airflow obstruction 
and a ratio of FEV1/FVC < 0.7 post bronchodilator confirms the diagnosis of persistent 
airflow limitation and hence COPD.21  As shown in Table 1.2, COPD is classified into 
stages according to the (GOLD) criteria.36 
 
Table 1.2 Classification of COPD according to severity of airflow obstruction.   
Adapted from the Global strategy for the diagnosis, management, and prevention of 
chronic obstructive pulmonary disease (Revised 2011), Global Initiative for Chronic 
Lung Disease36 
Specific spirometric cut-off points (e.g., FEV1/FVC < 0.7, FEV1 < 80, 50, 30 % 
predicted) are used for simplicity, but have not been clinically validated.36  These fixed 
Severity GOLD Stage Post-Bronchodilator FEV1 Criteria 
Mild GOLD Stage I FEV1 ≥ 80% predicted 
Moderate GOLD Stage II 50% ≤ FEV1 < 80% predicted 
Severe GOLD Stage III 30% ≤ FEV1 < 50% predicted 
Very Severe GOLD Stage IV FEV1 < 30% predicted 
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ratios may result in over-diagnosis of COPD in the elderly, especially in those with mild 
disease because the process of ageing does affect lung volumes.36  The predicted values 
are calculated depending on age, sex, height, weight and ethnicity as well as the research 
study.   
Spirometry is also used in the diagnosis of asthma.19  The two main measurements 
used are FEV1 and FVC and the ratio of FEV1/FVC is often used by respirologists to 
assess lung function.   
1.4.2 Plethysmography 
A full body MedGraphics’ Elite Series stand-alone body plethysmograph 
(MedGraphics Corporation.  350 Oak Grove Parkway St.  Paul, MN USA), as shown in 
Figure 1.6.C, is a device used to measure lung volumes.  The various lung volumes are 
shown in Figure 1.7 and their definitions are as follows- tidal volume (TV) is the amount 
of air inhaled or exhaled in one breath during relaxed, quiet breathing (typical value in an 
average young adult male-500ml), inspiratory reserve volume (IRV) is the amount of air 
in excess of tidal inspiration that can be inhaled with maximum effort (typical value in an 
average young adult male-3000ml), expiratory reserve volume (ERV) is the amount of air 
in excess of tidal inspiration that can be exhaled with maximum effort (typical value in an 
average young adult male-1200ml), residual volume (RV) is the amount of air remaining 
in the lungs after maximum expiration; keeps alveoli inflated between breaths and mixes 
with fresh air on next inspiration (typical value in an average young adult male-1200ml), 
vital capacity (VC) is the amount of air that can be exhaled with maximum effort after 
maximum inspiration (VC= ERV+TV+IRV); used to assess strength of thoracic muscles 
as well as pulmonary function (typical value in an average young adult male-4700ml), 
inspiratory capacity (IC) is the maximum amount of air that can be inhaled after a normal 
tidal expiration (IC= TV+IRV,  typical value in an average young adult male-3500ml), 
functional residual capacity (FRC) is the amount of air remaining in the lungs after a 
normal tidal expiration (FRC= RV+ERV, typical value in an average young adult male-
2400ml), total lung capacity (TLC) is the maximum amount of air the lungs can contain 
(TLC= RV+VC, typical value in an average young adult male-5900ml).14 
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Measurement of lung volumes requires a method of estimating the volume of gas 
inside the thorax.  The body plethysmograph uses the small fluctuations in pressure inside 
a sealed box containing the patient during breathing to calculate the volume of gas in the 
thorax.37  The basic principle behind the body box is Boyle’s law (shown in equation 2, 
which states that for a given mass of gas, the product of pressure and volume remains 
constant provided that the temperature does not change- 
P1 x V1 = P2 x V2 (2)  
Figure 1.6 Spirometry and Plethysmography 
 (A) A hand-held spirometer (B) A sample airflow curve obtained from the spirometer 
used to calculate FEV1 and FVC (C) A whole body plethysmograph 
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Where P1 and V1 are the pressure and volume of gas and P2 and V2 are the pressure and 
volume of the same mass of gas after a change in pressure and volume.37  To measure 
lung volumes, the patient sits inside a sealed body box.  Inside the box there are two 
masses of gas: one in the thorax and one outside the body but inside the chamber.  The 
patient breaths through a mouthpiece with a shutter and performs a series of “pants” 
(shallow rapid breathing).  During these “pants” the stutter closes but the subject 
continues to pant against the closed shutter.  The fluctuations in the box pressure are 
measured and the volume fluctuations are calculated.  At the same time a pressure 
transducer inside the mouthpiece records the pressure changes within the mouth which 
can be used as a surrogate for pressure changes inside the lungs.  Using these values and 
Boyle’s law, FRC can be calculated.  Measuring airflow through the mouthpiece during 
tidal breathing, maximum inspiration and maximum expiration allows us to calculate all 
the other lung volumes.   
Figure 1.7 Sample airflow curves obtained through a plethysmograph 
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The body plethysmograph attached to a Medgraphics gas analyzer (MedGraphics 
Corporation.  350 Oak Grove Parkway St.  Paul, MN USA) is also used to measure the 
diffusing capacity of the lung for carbon monoxide (DLCO) which is a surrogate 
measurement for diffusion of oxygen across the alveolar membrane into the blood.  
Carbon monoxide (CO) has similar physical properties as oxygen in terms of its 
solubility and ability to diffuse across membranes.  It also has the added advantage of 
being very strongly bound to hemoglobin, so that the entire CO transferred across the 
alveolar wall is retained within the blood and is not exhaled.  DLCO is measured by first 
instructing the subject to exhale to RV and then inhaling to TLC.  During this inhalation 
the subject inhales a known concentration of CO (0.3%) and helium (10%) with air.38  
After that the subject holds their breath for 8 seconds before exhalation which gives 
enough time for the CO to diffuse across the alveolar membrane.  The volume of gas is 
then collected and analyzed.  The exhaled concentrations of CO and helium are compared 
to the inhaled concentrations and after correcting for anatomical dead space, the amount 
of CO diffusing across the alveolar membrane is calculated.  There should be at least two 
acceptable tests that meet the repeatability criteria of either being within 3 mL CO 
(STPD).  min-1.mmHg-1 (or 1 mmol.min-1.kPa-1) of each other or within 10% of the 
highest value.38  The average of at least two acceptable tests that meet this repeatability 
requirement should be reported.  Pulmonary conditions such as emphysema reduce the 
surface area to volume ratio of the alveoli and hence the DLCO reported in subjects 
suffering from emphysema is often found to be lower than healthy subjects. 
1.4.3 Six minute Walk Test 
The six minute walk test (6MWT) is safe and easy to administer walk test, and is 
well tolerated and better reflects activities of daily living than other walk tests (example 
the shuttle walk test).39  The 6MWT is a self-paced exercise test that measures the total 
distance the subject can walk on a flat surface in 6 minutes.  In severe COPD subjects, 
the 6MWT has been shown to be a better predictor of mortality than traditional markers 
(FEV1 and Body Mass Index) of disease severity.40 
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1.4.4  St.  George’s Respiratory Questionnaire 
The St George’s Respiratory Questionnaire (SGRQ) is a well established, self-
reported health status questionnaire developed for COPD and asthma.41  The 
questionnaire contains three component scores: symptoms, activity and impact on daily 
life and a total score.42  The total score goes from 0 to 100 and higher scores indicate 
more severe limitation.  In both asthma and COPD, SGRQ has been shown to be a valid 
measure of impaired health in chronic airflow limitation and is repeatable and sensitive.43 
1.5 Pulmonary Imaging 
There have been tremendous improvements in pulmonary imaging techniques 
during the last two decades.  The advancement of imaging methods has improved our 
ability to diagnose, characterize and quantify pulmonary pathology.  These imaging 
methods provide a noninvasive method of acquiring functional as well as structural 
pulmonary information.  The technological improvements in  computed tomography (CT) 
and magnetic resonance imaging (MRI) have led to the development of new techniques 
for pulmonary imaging, and recent advancements in nuclear medicine techniques such as 
positron emission tomography (PET) have made noninvasive characterization of lesions 
possible.44  New methods of pulmonary imaging using CT and MRI have been used to 
evaluate pulmonary ventilation and perfusion and to detect small airways disease.44  
There has been developmental progress made towards transitioning to digital chest 
radiography, which is starting to replace more traditional methods of acquisition, 
transmission and viewing of chest radiographs. 
1.5.1 Chest X-Ray  
X-rays are a form of electromagnetic radiation and on account of their high 
frequency and energy are able to pass through a patient’s body and on a X-ray film thus 
producing an image.45  While passing through a patient’s body, the X-ray beam is 
attenuated by a varying magnitude by different organs depending on the density and 
atomic number of the tissue.  X-rays turn the X-ray film black, and hence the less dense 
the material, the more X-rays get through and the darker the film.  Hence, materials of 
low density appear darker than objects of high density on the X-ray film.  Chest X-rays 
 are usually the first imaging method used for pulmonary disease diagnosis because they 
are inexpensive, widely ava
visualization of pulmonary structures like 
mediastinum and hilar regions and the diaphragm a
commonly used X-ray techniques for the assessment of the lung are the posterior to 
anterior (PA) and lateral views taken at TLC.
be rotated anteriorly, so that they are project away from the lungs and are out of the field 
of view (FOV).  During a PA scan, the patient 
against the X-ray film.  The X
the PA direction.  In the lateral view, the patient is positioned with their side up against 
the film with their arms over 
account of the differences
appear as different signal intensities
rays much more than the lung tissue appears bright whereas the lungs appear dark 
because the attenuation caused by the lungs is minimal
The average dose from a chest X
natural environmental background radiation is approximately 0.01 mSv/day,
there are places on earth that have values that are 5
Figure 1.8 Chest X-Ray of a 63 year old male COPD Stage III subject
(A) P-A view (B) Lateral View.  Adapted from Parraga et. al (2007).
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average environmental exposure of 0.01 mSv/day, the average dose from a PA chest X-
ray is equivalent to that a person receives from the environment in about 2 days.  Ionizing 
radiation, such as X-rays, is capable of creating ions by knocking electrons out of their 
orbits.  When biological molecules are exposed to X-rays, these X-rays interact with the 
water molecules within the body leading to the formation of hydroxyl radicals.  These 
radicals then interact with the nearby Deoxyribonucleic acid (DNA) to cause strand 
breaks or base damage.  X-rays are also capable of ionizing DNA directly.  While 
radiation-induced damage is repaired within the cell, DNA double-strand breaks are more 
difficult to repair and occasional misrepair can lead to induction of point mutations, 
chromosomal translocations and gene fusion which are all linked to cancer induction.50  
Therefore, the low radiation dose, along with quick acquisition time, is a very important 
advantage of a chest X-rays compared to CT.  Various lung structure abnormalities can 
be identified using a chest X-ray such as flattening and increased translucency of the 
diaphragm which is commonly associated with gas trapping in respiratory disease.  
However, in a chest X-ray, all the anatomical structures are super-imposed on top of one 
another making it difficult to diagnose diseases like COPD, particularly in early disease 
stages.  Hence chest X-rays are used for assessment of more advanced morphological 
lung changes in COPD.51 
1.5.2 X-ray Computed Tomography 
X-ray CT is another major imaging modality used in the evaluation of pulmonary 
disease.  Traditionally, CT images are a two-dimensional representation of a cross-
sectional slice through a region of interest in the body.47  The third dimension of the 
image is the slice thickness which could range from 1 to 10mm.47  These cross-sectional 
images are obtained by using X-rays being emitted by an X-ray tube on one side of the 
gantry with a set of detectors on the other.  The patient passes through the gantry that 
rotates around at the level of interest.  Information from the detectors is analyzed by 
computers and displayed as an image.  Owing to the use of computer algorithms, a much 
greater array of densities can be displayed compared to conventional X-ray films.  This 
allows for differentiation of solid organs from each other and from pathological processes 
such as tumors and fluid collection.  It also makes this imaging modality extremely 
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sensitive to the presence of minute amounts of fat, calcium or contrast material.  As with 
a chest X-ray, high density objects attenuate the X-rays to a higher magnitude and 
therefore appear as lighter gray than objects of lower density, which appear darker.45  
White or light gray objects are therefore called ‘high attenuation’ whereas dark grey and 
black objects are called as ‘low attenuation’.  In a CT scan, image information can be 
manipulated to highlight the organ of the body being studied.  This is called ‘altering the 
window setting’.45  For example, in a chest CT where a wide range of tissue densities are 
present, a good image of the mediastinal structures shows no lung details.  However, the 
lung parenchyma can be observed in full detail by setting a lung window.   
The CT image is composed of multiple pixels and images are usually 512 pixels 
by 512 pixels.  The pixel area multiplied by the slice thickness defines the voxel volume.  
The X-ray attenuation of the structures within a voxel is averaged to produce the 
attenuation value for the voxel that is recorded to produce an image.  Each voxel in a CT 
image is assigned a Hounsfield unit (HU)52  based on its attenuation coefficient relative to 
that of distilled water at room temperature as shown in equation (3).   
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where µx is the linear attenuation coefficient of the object and µwater is the linear 
attenuation coefficient of water.  Based on this, water is assigned a value of 0 HU, while 
air has a value of -1000 HU and all the tissues with an attenuation coefficient higher than 
that of water (materials denser than water) are assigned positive HU values.53  
Standardization of the units allows for direct comparison between scans acquired on 
different scanners made by different manufactures. 
 Emphysema is pathologically 
of air spaces and therefore these air filled regions have HU values closer to that of air 
than healthy tissue and appear dark in CT scans
basic patterns of emphysema that ca
Centrilobular emphysema is typically more pronounced within the upper lobes and in CT 
images shows up as regions of decreased attenuation, without 
confined to the center of the secondary lobule.
with panlobular emphysema ar
CT images, it is characterized by large regions of low attenuation leading to an apparent 
simplification of lung architecture.
using CT images by using a HU threshold to quantify the volume of the lung below the 
threshold. 
The biggest disadvantage of CT is related to its use of high doses of ionizing 
radiation, hazards of intravenous contrast, lack of portability of 
relatively high cost.  An average abdominal CT scan has a dose of 10 mSv, which is 
equivalent to 500 chest X
COPD, there is a need for following the patients serially over years for evaluating disease 
progression and response to treatment which means getting regular CT scans a
Figure 1.9 X-ray computed tomography (CT)
(A)  CT center slice from a
60 year old female COPD stage 2 subject
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exposing the patients to high levels of ionizing radiation.  There is a lot of concern about 
exposing the patients to high amounts of ionizing radiation since there is an increased risk 
of radiation-induced cancer from cumulative dose related to repeat CT scans.54  
Assessment of emphysema using CT scans also has certain other limitations like low 
specificity, low sensitivity in the evaluation of mild disease and considerable inter-
observer variability in the interpretation of the findings.55  
1.5.3 Nuclear Medicine 
Nuclear medicine involves the administration of small amounts of compounds 
labeled with radioactivity (radionuclides) that are used to provide diagnostic information 
in a wide range of diseases.  It involves injecting a compound into the body which is 
labeled with a gamma-ray-emitting or positron-emitting radionuclide.  The radio labeled 
compound is called a radio-pharmaceutical, or more commonly as tracer or radiotracer.  
When the radionuclide decays, it emits gamma rays or high-energy photons.  These 
gamma rays or photons have sufficient energy so that they can exit the body without 
being scattered or attenuated.56  Gamma cameras are attached around the bore of the 
scanner which can detect these rays or photons and form an image of the distribution of 
the radionuclide.56  There are two main classes of nuclear medicine imaging: single 
photon imaging [which includes scintigraphy and single photon emission computed 
tomography (SPECT)] and positron imaging [positron emission tomography (PET)]. 
Scintigraphy uses radionuclides and gamma cameras to form two-dimensional 
images and can be thought of as being the nuclear medicine equivalent of a chest X-ray.  
Lung ventilation scintigraphy can be performed using radioactive gases57 or labeled 
aerosols58.  The radioactive gases most commonly used for lung scintigraphy are xenon 
and krypton (133Xe,127Xe and 81mKr).57  The images formed are a two-dimensional 
projection of the organ being studied.  Although planar scintigraphy imaging is still 
commonly used to study pulmonary ventilation and perfusion, the introduction of the 
more advanced three-dimensional SPECT about 20 years ago made scintigraphy obsolete 
in several fields. 
SPECT is similar to scintigraphy and can be thought of the CT equivalent of 
nuclear medicine.  Multiple projections (scintigraphs) are acquired at different gamma 
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camera positions and all the images are reconstructed into a volume which can then be 
analyzed on a slice by slice basis.  This enables cross-sectional images to be 
reconstructed, providing the depth information missing from planar scintigraphy.  Some 
of the radioactive isotopes used for SPECT are 133Xe, 127Xe, 81mKr and a particular 
aerosol: Technegas, which is called as “pseudo-gas” because of its very small particle 
size, giving it properties similar to that of a gas.59,60  SPECT can be used to analyze 
ventilation and perfusion in the lungs.  Matching of ventilation and perfusion is critical 
for efficient gas exchange and therefore oxygen supply to the tissue.61  Ventilation can be 
studied using various tracer gases like 133Xe or technetium 99m (99mTc).62,63  Evaluation 
of wash-in, breath-hold and wash-out phases using a tracer gas can help in detection of 
functional abnormalities in lung volumes and study ventilation patterns, thus making it 
sensitive to gas trapping and areas of high resistance within the bronchial tree.62,63  
It is critical to study the perfusion pattern along with the ventilation pattern 
because without perfusion, gas exchange cannot happen even if there is perfect 
ventilation.  The most common radiopharmaceuticals used for perfusion lung imaging are 
99mTc labeled macro-aggregated albumin (MAA).47  Prior to the scan the radio-labeled 
particles of MAA, marked with 99mTc are injected into the peripheral vein.57  These 
particles are 15-100 µm in size and get lodged in the pulmonary capillaries and pre-
capillary arterioles as they move along in the blood stream.  The particle distribution 
accurately illustrates regional perfusion.  It is critical to account for the number of 
particles given to the patient.  A minimum of 60000 particles are required to obtain an 
even distribution of activity reflecting regional perfusion.64  Normally, about 400,000 
labeled particles are injected.57  Bearing in mind that there are over 280 billion 
pulmonary capillaries and 300 million pre-capillary arterioles, the routinely administered 
particles will result in the blockage of only a small fraction of pulmonary vessels.57  
MAA is eventually broken down by the body and the obstruction in the arterioles will be 
removed and normal blood supply will resume.  Since 99mTc is radioactive,65 a radiation 
dose is given to the subject with each SPECT scan.  A ventilation scan with 99mTc has an 
effective dose between 0.1 - 0.6 mSv, depending on the protocol and a perfusion scan has 
an effective dose of 1.0 mSv.66  A single gamma ray is emitted when each of the isotopes 
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used in the scan undergoes decay which is then detected by the gamma camera and the 
image is reconstructed. 
Similar to SPECT imaging, positron emission tomography (PET) images contain 
structural and functional information of an organ acquired from decaying nucleotides by 
emission of photons.  PET involves the administration of a radioisotope that decays by 
emitting a positron.  The positron annihilates with an electron producing two 511-keV 
anti parallel photons.57  The two photons have to travel 180 degrees from each other in 
order to conserve momentum.67  Radionucleotides used in PET imaging are 11C, 13N, 15O, 
18F, 19Ne and 68Ga.68  Fluorodeoxyglucose ([18F] FDG) is the most widely used PET 
tracer in clinical practice as it has the longest half life (110 minutes) among all the 
elements used for PET.68  During a scan the patient lies in a supine position in the bore of 
the scanner which is completely surrounded by gamma cameras.  When an annihilation 
event happens, the emitted photons travel in opposite directions and strike the gamma 
cameras at the opposite side of the bore.  There is usually a difference in the arrival times 
of these two photons as the distance they have to travel to get to the cameras is not 
identical, unless the annihilation happens exactly at the bore of the scanner.  The 
difference in arrival times of anti-parallel photons is used to localize the position of the 
annihilation and spatially identify the areas of annihilation.67  Based on all the 
annihilation data, a computer algorithm can construct the PET image.  
1.5.4 Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) is a powerful, noninvasive imaging modality 
that has experienced rapid growth over the last 10-15 years.  MRI does not use ionizing 
radiation to produce images and hence does not give a radiation dose to the patients like 
CT, SPECT or PET.  MRI is based on the fact that when hydrogen nuclei are placed in a 
magnetic field and stimulated by radio waves of a particular frequency, they emit some of 
the absorbed energy in the form of radio signals.  These signals can be used to create an 
image.69  The advantages of MRI compared to CT are the lack of ionizing radiation; 
increased soft tissue contrast; the ability to directly image in coronal, sagittal or oblique 
planes as well as the transverse plane and the intrinsic contrast in the blood vessels as a 
result of flow phenomenon.   
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Pulmonary imaging using Conventional Proton (1H) MRI 
The lung is the most difficult organ to image using the conventional 1H MRI.70,71  
Problems associated with lung imaging include intrinsically low hydrogen proton density 
within the lung, local field inhomogeneities and cardiac and respiratory motion.72  
Approximately 70% of the healthy lung is filled with air, which has minimal hydrogen 
proton density,  making it extremely difficult to acquire any structural and function 
information using conventional proton MRI.72  On account of the vastly different 
properties between air and tissue, the countless interfaces between air and tissue generate 
susceptibility artifacts that result in a loss of signal of fine structures such as alveolar 
septae.72  Magnetic susceptibility is the measure of the strength of the magnetic field that 
the external magnetic field creates in a material. Susceptibility artifacts occur as a result 
of microscopic gradients or variations in magnetic field strength that occur near the 
interface of substances of different magnetic susceptibility such as air and tissue. The 
result is the formation of bright and dark areas with spatial distortion of surrounding 
anatomy.  Cardiac and respiratory motion also causes motion artifacts in the images due 
to the relatively large image acquisition time.70  The motion artifacts in the images can be 
minimized by acquiring the MRI under breath-hold conditions, although this means 
severe constrains on the duration of image acquisition.  Figure 1-10 shows a 
conventional proton MRI center slice of the lung.  As can be observed, the lungs appear 
as two “black holes” on the MRI which makes it difficult to extract functional or 
structural information about lung anatomy from the images.  However, recently there 
have been developments that have led to the mitigation of these problems. 
 
 Some of the new techniques developed recently are ultra
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the alveolus into the pulmonary vasculature.  Initial studies with oxygen enhanced MRI 
in patients with emphysema showed ventilation defects corresponding to bullous changes 
in the lungs.28  This method has been able to show significant differences between 
subjects with and without emphysema and has an excellent correlation with FEV1 and 
DLCO.28,81  Oxygen-enhanced MRI has been able to show differences in regional 
ventilation in human subjects.  Fourier decomposition in proton MRI is another imaging 
method that has been used for non-contrast-enhanced regional lung perfusion and 
ventilation studies.77  It has also been shown that there is qualitative agreement in the 
assessment of regional lung ventilation and perfusion between Fourier decomposition 
proton MR imaging and conventional SPECT/CT in an animal model.82  High resolution 
ventilation distribution maps have been characterized with this method.83  All these 
methods have undergone rapid development in the past few years and hold promise in the 
future.  Another method that has been extensively used to study the structural and 
functional pulmonary pathology has been hyperpolarized noble gas MRI. 
Hyperpolarized Noble Gas MRI 
Hyperpolarized noble gas MRI had been used over the last 2 decades to study 
lung structure and function.  This method was first developed by Albert and colleagues in 
1994.84  In conventional MRI, the signal intensity of the image depends on the total 
magnetization in the chosen sample volume element.  When a sample containing protons 
is kept in an external magnetic field, all the protons like up either in the parallel or the 
anti-parallel direction to the magnetic field.  The number of protons lined up with the 
field is slightly higher than that of protons lines up against the field.  The ratio of the 
number of protons lines up with the field to that of the number of protons liked up against 
the field is called the polarization and in large magnetic fields, thermal-equilibrium 
polarizations reach close to 10-5 meaning that the probability of excess spins being 
aligned with the field is about 1 in 100000.  But with the massive number of protons in 
the human body, even this minute probability is enough to get good quality images.  
However, for inhaled contrast agents, the concentration is not enough to be used in 
conventional high-speed, high-resolution MR scanners.84  In hyperpolarized noble gases, 
the polarization is boosted before the patient inhales the gas in a process known as 
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hyperpolarization.  This process allows for better signal from the inhaled contrast agent 
and gives better quality images by increasing the polarization of the gas by four to five 
orders of magnitude.85  The polarization of 129Xe and other spin ½ noble gases can be 
enormously enhanced through a process known as spin-exchange with an optically 
pumped alkali metal vapour such as rubidium (Rb).  During optically pumping, circularly 
polarized laser light is directed into a glass cell containing a vapour of Rb and the noble 
gas.  This causes a transfer of angular momentum form the light to the electrons of the Rb 
and the Rb atoms are said to be polarized.  When these Rb atoms collide with the noble 
gas atoms, there is a transfer of angular momentum form the Rb to the noble gas.  The 
transfer of angular momentum happens from the electron spins of the Rb to the nuclear 
spins of the noble gas.  The wavelength of light required to polarize the electrons in Rb 
and get the hyperpolarization process started is 794.8 nm.85  Although the first 
experiments in hyperpolarized gas MRI were done using 129Xe gas,84 3He has been the 
contrast agent of choice since then due to the nearly 3-fold gyromagnetic ratio of 3He 
(3He:32.4MHz/T,129Xe: 11.8 MHz/T)86 and higher enrichment, both of which lead better 
signal with 3He than 129Xe.  
Hyperpolarized 3He MRI has been used to study the structural and functional 
changes in diseases like COPD,3,5,87-91 asthma,92-100, CF101-103 and radiation induced lung 
injury (RILI),104,105 lung cancer106 and lung transplant107-109.  The main application of 
hyperpolarized noble gas lung imaging is to study the structural and functional features of 
the lung, quantify these measurements and monitor the changes longitudinally.  The two 
main measurements used for these applications are ventilation defect percent (VDP)110,111 
and apparent diffusion coefficient (ADC)3,98,112.  Figure 1.11 shows hyperpolarized 3He 
MRI images for a healthy volunteer (A), subject with COPD (B), asthma (C) and CF (D).   
  
Figure 1.11 Hyperpolarized 
(A) 26 year old female healthy 
(B) 77 year old female stage 3 COPD subject with FEV
(C) 50 year old female asthma subject with FEV
(D) 38 year old male CF subject with FEV
The yellow arrows indicate regions of abnormal ventilation called ventilation defects
 
 
 
3He MRI images 
volunteer with FEV1%pred = 92 and FEV1/FVC = 91
1%pred  = 50 and FEV
1%pred  = 71 and FEV1/FVC = 68
1%pred  = 49 and FEV1/FVC = 55
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Ventilation defect percent (VDP) is the measurement of the percentage of the lung 
that is not being ventilated.  “Defects” in the lungs are the areas of the lungs that appear 
dark in a hyperpolarized noble gas MRI and represent regions of the lungs that are hypo-
ventilated or not ventilated at all.  These regions have been highlighted using arrows in 
Figure 1.11.  The earliest pulmonary imaging study using 3He MRI studied a single 
healthy volunteer and showed that 3He MRI images were able to show a sharp 
demarcation of the lungs against the diaphragm, heart, chest wall and blood vessels 
which do not give any signal.113  This study also showed that the signal intensity within 
the air spaces was proportional to the concentration of the 3He gas and hence proportional 
to the actual ventilation within that region of the lungs.113  Bachert et al.  showed that the 
signal distribution in a healthy volunteer was highly homogeneous within the lungs with 
a signal void for vascular and cardiac structures.114  This study also suggested that 3He 
MRI could be a viable alternative to the established methods for pulmonary imaging all 
of with used ionizing radiation.114  The first multi-subject study using 3He MRI was 
performed by Kauczor et al. who studied static ventilation images obtained using 3He 
MRI in healthy volunteers as well as subjects with pulmonary diseases.115  Kauczor et al. 
observed that there was homogeneous signal intensity over the lungs and hence uniform 
ventilation for the healthy volunteers.  In subjects with COPD and other lung conditions, 
they found that the signal intensity was highly heterogeneous with the presence of large 
wedge-shaped “ventilation defects”.  This study demonstrated that it was possible to 
distinguish between healthy subjects and patients suffering from pulmonary diseases 
using hyperpolarized noble gas MRI.  Subsequently there were studies that found good 
correlation between ventilation defects observed with hyperpolarized 3He and xenon-133 
scintigraphy.116,117  Studies have also shown good correlation between ventilation defect 
scores assessed using 3He MRI and 81mKr scintigraphy for a group of healthy subjects and 
COPD patients.118  The defect scores calculated using 3He MRI were also found to be 
well correlated with high resolution computed tomography (HRCT) and pulmonary 
function tests.118  3He MRI was shown to be more sensitive than CT at detecting 
ventilation defects in lung transplant candidates.119  For CF patients, McMahon et al.  
found a strong correlation between 3He MRI and HRCT measurements and between 3He 
MRI measurements and FEV1 and FVC.120  
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Other studies have also found a good correlation between 3He MRI measurements 
and the gold standard for pulmonary imaging- CT as well as 3He MRI measurements and 
spirometry.91,121,122  The safety profile of hyperpolarized 3He gas has also been studied 
and found to be safe for administration to healthy subjects, heavy smokers and those with 
obstructive lung disease.117,123,124  
Mathew et al.  studied the reproducibility of hyperpolarized 3He measurements in 
healthy volunteers and COPD subjects and found the ADC reproducibility to be high for 
same day as well as 7-day rescan.125  Same-day reproducibility for ventilation defect 
volume (VDV) was also found to be high, and 7-day reproducibility for VDV was 
moderate.125  Niles et al.  studied the reproducibility of 3He MRI measurements in 
subjects with exercise induced bronchoconstriction and found that inter-day and inter-
reader reproducibility was generally high when using the same method for image analysis 
at the two sites involved in the study.97  Parraga et al. studied the reproducibility of 
ventilation defects in healthy elderly subjects and found that there was high 
reproducibility for same day re-scan and moderate to high reproducibility for 7-day 
rescan.126  Diaz et al. studied the reproducibility of 3He MRI ADC measurements in 
healthy volunteers and patients with emphysema for three visits over 7 days.127  They 
reported high reproducibility in ADC measurements for healthy subjects as well as 
patients with emphysema over the three visits.127  Parraga et al. studied the 
reproducibility of 3He MRI ADC and ventilation defect measurements in healthy 
volunteers and COPD patients scanned three times, twice within 10 minutes and again 7 
± 2 days later and reported excellent same-day and 7-day ADC reproducibility as well as 
excellent reproducibility for same-day ventilation defect scoring and ventilation defect 
volume (VDV).3  Hence, hyperpolarized 3He MRI has been shown to be a safe, non-
invasive and reproducible method for studying lung structure and function and has the 
added advantage that it does not use ionizing radiation.  However, there are certain 
problems with 3He MRI that has made its clinical transition virtually impossible, at least 
with the technology that is available at this moment. 
During the last decade or so the demand for 3He gas has gone up tremendously 
and its cost has skyrocketed.  The cost of 1 liter of 3He gas has gone up from $100 a 
couple of years ago to more than $2100 according to a recent report.128  There has been a 
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very high demand for 3He gas from the US Department of Homeland Security (DHS) and 
Department of Energy (DOE) which has led to the US inventory of 3He plunging from 
200,000 liters in 2001 to somewhere between 43,000 – 48,000 in 2010.128  DOE 
anticipates that it will have less than 8000 liters per year of 3He to sell for the next few 
years while the demand is expected to rise from the 76000 liters in 2009.128  In the wake 
of the 9/11 terrorist attacks, the DHS initiated a program to install more than 1400 
radiation monitors at ports and border crossings which need 3He gas to function.129  This 
huge demand came at the same time that there was a dip in supply of 3He due to a 
reduction of nuclear weapons production.129  3He gas is produced when tritium (used to 
boost the yield of nuclear weapons) decays and when there was a reduction in nuclear 
weapons production, naturally there was a dip in tritium decay and hence production of 
3He.129  By early 2009, the total demand for 3He in the United States was over 213,000 
liters and the supply was 45,000 liters.129  Although theoretically tritium could be 
manufactured in commercial reactors to help meet the 3He demand, the cost would be 
enormous- more than $20,000 per liter by one estimate and would take more than 20 
years to yield sufficient quantities of 3He.128  The increasing price and the lack of 
availability of 3He has forced the hyperpolarized noble gas pulmonary imaging field to 
look for alternatives to 3He as a contrast agent and 129Xe has emerged as a good prospect.   
129Xe is much more abundant as compared to 3He and is much cheaper as well.  
After the first study of hyperpolarized noble gas pulmonary imaging was reported using 
129Xe,84 the field transitioned to using 3He as a contrast agent as it had a simpler and more 
mature polarization technology,85 a larger magnetic moment and absence of physiological 
effects.130  However, recently there has been a resurgence in 129Xe MRI research leading 
to development of methods to improve the volume of polarized gas required for research 
and clinical studies as well as the polarization of the gas itself.130-134  Xenon has had a 
long history of being a safe contrast agent in CT studies.135  The safety profile of 129Xe 
MRI has also been studied and found to be safe in healthy volunteers as well as 
obstructive and restrictive pulmonary disease subjects.130,136  Recently there have been 
studies undertaken to compare 3He MRI measurements with 129Xe MRI 
measurements.137-139  Results have shown that although there are differences in the 
physical properties of 3He and 129Xe, 129Xe is potentially an excellent alternative for 3He 
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in pulmonary imaging studies.  There have also been other studies to investigate 
pulmonary diseases using 129Xe as a contrast agent.131,140-143  However, there have not 
been any studies to investigate the reproducibility of hyperpolarized 129Xe MRI 
measurements over short periods of time. 
  Studying the reproducibility of 129Xe measurements over short periods of time is 
critical in clinical study design.  For example, in longitudinal clinical studies that aim to 
use 129Xe MRI measurements of disease, it will be critical to understand variability that 
can be attributed to 1) image acquisition methods, including those related to the scanner 
(field strength, coils used) and subject compliance (breath-hold, motion), 2) image 
analysis methods that are observer-dependent or computationally driven, 3) site specific 
methodologies including hyperpolarization of the gas and the gas delivery methods, 4) 
potential physiological and radiological changes that occur over short periods of time.  In 
order to be confident about the physiological differences being observed in pulmonary 
diseases, we first have to be confident about the reproducibility of the measurement being 
used to study these physiological changes.   
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Figure 1.12 Hyperpolarized 129Xe MRI images  
(A) 26 year old female healthy volunteer with FEV1%pred = 92 and FEV1/FVC = 91 
(B) 77 year old female stage 3 COPD subject with FEV1%pred  = 50 and FEV1/FVC = 50 
(C) 50 year old female asthma subject with FEV1%pred  = 71 and FEV1/FVC = 68 
(D) 38 year old male CF subject with FEV1%pred  = 49 and FEV1/FVC = 55 
The yellow arrows indicate regions of abnormal ventilation called ventilation defects 
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Figure 1.13 Hyperpolarized 129Xe ADC maps  
(A) 26 year old female healthy volunteer with FEV1%pred = 92 and FEV1/FVC = 91 
(B) 77 year old female stage 3 COPD subject with FEV1%pred  = 50 and FEV1/FVC = 50 
(C) 50 year old female asthma subject with FEV1%pred  = 71 and FEV1/FVC = 68 
(D) 38 year old male CF subject with FEV1%pred  = 49 and FEV1/FVC = 55 
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1.6 Thesis Hypotheses and Objectives 
Hyperpolarized noble gas lung imaging allows us to acquire high temporal and 
spatial resolution structural and functional images of healthy volunteers and subjects with 
obstructive and restrictive pulmonary diseases.  These images allow us to visualize the 
ventilation pattern in the lungs and identify regions of no ventilation known as 
“ventilation defects”.  The lung microstructure can also be studied using the apparent 
diffusion coefficient measurement.  Since the first pulmonary images using 
hyperpolarized noble gas were acquired in 1994, there have been significant 
improvements in the quality of the images acquired.  There has also been development of 
various measurements to study the structural and functional changes taking place in the 
lungs after the onset of disease.  However, while there have been multiple studies 
investigating the reproducibility of hyperpolarized 3He MRI measurements; there have 
not been any to investigate the reproducibility of 129Xe measurements.  Hence the 
overarching aim of this thesis was to investigate the intra-observer and inter-observer 
reproducibility of hyperpolarized 129Xe MRI measurements.  We wanted to study the 
reproducibility of the VDP measurement for healthy volunteers and subjects with COPD 
for same day rescan and 1-week rescan.  We also wanted to investigate the differences 
between two-dimensional (2D) and three-dimensional (3D) image acquisition methods 
for 129Xe static ventilation images.  We hypothesize that the 129Xe MRI VDP will be 
reproducible for repeated scans over short periods of time when no physiological change 
is expected to occur in the lungs.  We also hypothesize that there will not be any 
differences observed in the measurements obtained from 2D or 3D image acquisition.   
Chapter 2 describes the materials and methods used for this study.  Chapter 3 
outlines the results of the reproducibility analysis and chapter 4 presents the discussion 
and conclusion for the work and also includes the study limitations and directions for 
future work in the study of the reproducibility of the 129Xe MRI measurements. 
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2 CHAPTER 2: MATERIALS AND METHODS 
Chapter 2 provides details about the study design and the study subjects.  Details 
about the pulmonary function tests as well as image acquisition and data analysis 
methods are provided to help the reader better understand how the results presented in 
chapter 3 were acquired and analyzed.   
2.1 Study Subjects 
Five healthy volunteers (HV) and ten COPD subjects were enrolled from the 
general population and a local tertiary health care center.  All subjects provided informed 
written consent to the study protocol approved by the local research ethics board and 
Health Canada, and the study was compliant with the Personal Information Protection 
and Electronics Documents Act (PIPEDA, Canada) and the Health Insurance Portability 
and Accountability Act (HIPAA, USA).  COPD subjects required a disease diagnosis of 
at least 1 year, having had a smoking history of at least 10 pack-years and fewer than 
three COPD exacerbations within the previous 12 months.  COPD subjects were 
categorized according to the GOLD criteria.1  HV were included if they had no history of 
chronic respiratory disease, less than one pack-year smoking history, FEV1 greater than 
80% predicted, FEV1 divided by the FVC or FEV1/FVC greater than 70%, and no current 
diagnosis or history of unstable cardiovascular disease. 
Throughout the course of the study, COPD subjects were withdrawn from the 
study if they had experienced a COPD exacerbation or if they experienced a drop in 
arterial blood oxygen levels below 80% for 15 continuous seconds during MRI 
procedures as monitored using pulse oximetry.  After providing informed written 
consent, the subjects underwent physical examination and their vital signs were recorded 
followed by spirometry and plethysmography.  All subjects were screened for MRI safety 
and coil compatibility before the MRI session and at all times during the MR scan, an 
expert was present in the MRI suite with the subject to administer the gas to the subject 
and coach their breathing maneuvers.  The subjects breathed in 1L of gas from FRC to 
ensure uniformity in lung volume for all the scans.  This was useful in eliminating errors 
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in measurements due to differences in lung volume for the same subject due to 
differences in the volume of inhaled gas. 
2.2 Pulmonary Function Tests 
Spirometry was performed using an ndd EasyOne spirometer (ndd 
Medizintechnik AG, Zurich, CH) (Figure 1.6.A) measuring FEV1 and FVC with a 
minimum of three acceptable spirometry maneuvers with the best FEV1 and FVC 
selected for analysis according to American Thoracic Society (ATS) guidelines2 (Figure 
1.6.B).  Whole body plethysmography was performed using a MedGraphics’ Elite Series 
stand-alone body plethysmograph (MedGraphics Corporation.  350 Oak Grove Parkway 
St.  Paul, MN, USA) (Figure 1.6.C) for the measurement of total lung capacity (TLC), 
inspiratory capacity (IC), residual volume (RV) and functional residual capacity (FRC).  
A body plethysmograph attached to the Medgraphics gas analyzer was used to measure 
the DLCO.   
2.3 Image Acquisition 
129Xe MRI was performed on a whole body 3.0 Tesla Discovery 750 MR system 
(General Electric Health Care (GEHC), Milwaukee WI) with broadband imaging 
capability as previously described.3 Hyperpolarized 129Xe MRI was acquired using a 
custom-made, unshielded quadrature-asymmetric bird-cage coil tuned to 35.34MHz, as 
previously described.4,5  
129Xe gas (86% enriched) was polarized to 10-60% using a turn-key polarizer 
(XeBox-E10, Xemed LLC, New Hampshire, USA).  Doses of hyperpolarized 129Xe gas 
were dispensed directly into the pre-rinsed 1.0L Tedlar® bags pre-filled with 4He to 
generate a 50/50 mixture of 4He gas and hyperpolarized 129Xe gas.  Polarization of the 
diluted dose was measured using a Polarimeter (GEHC, Durham, NC). 
During the scanning visits, diffusion-weighted (DW) and non-diffusion-weighted 
(NDW) images were acquired during a breath-hold of a 1L 129Xe/4He mixture inhaled 
from FRC.  NDW images were obtained using a two-dimensional fast gradient recalled 
echo (2D FGRE) sequence with centric phase-encoding ordering as shown in Figure 
2.1.A.  Two interleaved images (16s total data acquisition, TE/TR/flip angle = 10 
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ms/13.5 ms/9o, bandwidth = 31.25 kHz, FOV = 40 x 40 cm, matrix 128 x 80, 7 slices, 
30 mm slice thickness, 0 gap), with and without additional diffusion sensitization (G = 
2.90 G/cm, gradient rise and fall time = 0.5 ms, gradient separation = 2 ms, gradient 
duration = 2.0 ms, diffusion time = 5 ms) were acquired. 
During the same visit, 129Xe MRI coronal static ventilation (SV) images were also 
acquired during a breath-hold of a 1L 129Xe/4He mixture inhaled from FRC (14s data 
acquisition, TE/TR/flip angle = 1.50 ms/6.7 ms/1o, bandwidth = 15.63 kHz, FOV = 40 × 
40 cm, matrix 128 × 128, 14 slices, 15 mm slice thickness, 0 gap) using a three-
dimensional fast gradient recalled echo 3D FGRE sequence as shown in Figure 2.1.B. 
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The NDW images were used to assess the 129Xe static ventilation reproducibility 
between the repeated scans.  The NDW images were acquired at multiple time-points and 
hence were used to study the reproducibility of 129Xe VDP over multiple time-points.  
Subjects were instructed to perform normal tidal breathing from room air before inhaling 
Figure 2.1 FGRE pulse sequences 
(A) 2D FGRE, (B) 3D FGRE, Gs = slice select gradient, GØ = phase encode gradient, Gf 
= frequency encode gradient, TR= repetition time, TE= echo time.  Adapted from 
Hornak, J.P, The Basics of MRI 10 
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the entire contents of the 1L dose bag mixture from FRC and perform a breath hold of 8-
15 seconds.  This training was important to minimize the potential for differences in the 
levels of inspired gas between the breath-hold scans for each subject.  The entire process 
of acquiring the xenon static ventilation images is illustrated in Figure 2.2.  The time 
frame between 129Xe scans was within 2 ± 1 minute for all subjects for the same day 
rescan and 7 days for the three COPD subjects who returned one week later for another 
visit.  The 3 subjects who returned for the 1-week rescan had two NDW scans done 
within 2 ± 1 minute of each other at the second visit.  A 1-week period between scanning 
sessions was selected to minimize subject inconvenience and to model typical sources of 
variability stemming from the acquisition of the images over a short period of time 
because of coil positioning, subject motion and positioning changes and potential short-
term physiological changes.  Repeat spirometry at the second MRI visit was performed to 
screen for exacerbations or global disease changes that may have occurred during the 1-
week scanning period.  
Figure 2.2 Image acquisition procedure 
Subjects were instructed to lay supine in the custom built 129Xe bird cage coil which was 
positioned inside the bore of the MRI.  The 129Xe gas was hyperpolarized using the 
polarizer and images were acquired during a breath-hold after the subjects inhale the 
entire contents of the bag.   
For all the subjects, 129Xe gas breath-holds followed standard full inspiration 
breath-hold 1H MRI with subjects scanned during a 1L breath-hold of medical grade 
nitrogen (N2) (Spectra Gases, Alpha, NJ) using the whole body radiofrequency (RF) coil 
and 1H fast spoiled gradient-recalled-echo sequence as previously described.3  
Hyperpolarized 3He MRI was enabled using a linear bird-cage transmit/receive 
chest coil (RAPID Biomedical GmbH, Wuerzburg Germany).  A turnkey system 
(HeliSpin™) was used to polarize 3He gas to 30-40% and doses (5mL/kg body weight) 
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were administered in 1.0L Tedlar® bags diluted with N2.  Hyperpolarized 3He MRI 
coronal SV images and NDW images were acquired during breath-hold of a 1L 3He/N2 
mixture as previously described.3  Figure 2.3 shows the sequence in which the scans 
were acquired and time-period between the scans.  The time-period between the 
consecutive scans acquired on the same day was 2±1 minutes.  The time-period between 
the two visits was exactly 1-week for all the 3 subjects who returned for the second visit.  
 
2.4 Image Analysis 
A single expert observer analyzed the 129Xe NDW and SV as well as the 3He 
NDW and SV images for regions of signal void known as ventilation defects using an in-
house software developed using MATLAB R2007b (The Mathworks Inc., Natick, MA, 
USA) as previously described.6  The analysis was performed within an image 
visualization room with background lighting levels consistent for all image analysis 
sessions and the entire analysis was repeated five times (5 rounds) as shown in Figure 
2.3.  For each round of analysis, the subjects and scans were randomized to minimize the 
observer bias in the analysis. A period of two days was left between consecutive rounds 
of analysis to minimize the possibility of observer bias between rounds.  To study the 
inter-observer reproducibility of 129Xe MRI VDP, a second observer analyzed the 
repeated 129Xe NDW and SV images once (1 round). 
Figure 2.3 Sequence of scans acquired 
1H= proton, NDW= non-diffusion-weighted, SV= static ventilation 
He= Helium-3, Xe= Xenon-129, PFTs= Pulmonary Function Tests 
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129Xe MRI and 3He MRI of COPD is typically characterized by heterogeneous gas 
distribution that is reflected in heterogeneous signal intensity for the SV and NDW 
images for an inspiration breath-hold scan.  To compare the distribution of 129Xe and 3He 
gas at different time-points within the lung, segmenting the 129Xe and 3He images was 
based on the voxel signal intensity.  A k-means clustering algorithm7 was used to classify 
the voxel intensity values into five clusters ranging from signal void (cluster 1, C1 or 
ventilation defect volume (VDV)) and hypo-intense (C2) to hyper-intense signal (C5).  
Briefly, it involved binning data points into cluster so that the data points in one cluster 
were as close to each other in signal intensity as possible and as far as possible from data 
points in other clusters.  Each cluster was defined by its member objects and the centroid.  
The centroids were chosen and through iterations all the data points were binned into 
clusters so the all the pixels in a particular cluster were within a range of signal intensity 
values.   An expert observer can usually distinguish between four visually obvious groups 
of signal intensities in pulmonary noble gas MRI- signal void, hypo-intense, normal 
intensity and hyper-intense.  The static ventilation and the non-diffusion weighted images 
were first normalized to the range of pixel intensities 0-255. Following that the full pixel 
intensity range of 0-255 was divided into four equal regions: 0-63, 64-127, 128-191, 192-
255 and the center of each interval was selected as a centroid.  After clustering, it was 
noticed that the cluster representing signal void contained some pixels with hypo-intense 
signal.  Hence, the first cluster was divided into four clusters and k-means was reapplied 
to it. The first two clusters of the resulting binning were classified as signal void and the 
other two clusters as hypo-intense signal, thus giving 5 clusters from C1-C5.  C1 included 
the minimum signal intensity regions within the lungs as well as the background.  A 
seeded region growing algorithm8 (SGRA) was used to segment out the thoracic cavity 
volume from the 1H images.  The clustered 129Xe/3He NDW and SV images were 
registered to the segmented thoracic cavity to exclude all the pixels in the background 
from C1 and only the pixels inside the thoracic cavity were included to generate C1-C5.  
For the purpose of analysis, the lung was divided into two regions- regions of signal void 
know as ventilation defect volume (VDV) or C1 and the regions of signal intensity 
known as ventilation volume (VV) obtained by combining C2-C5.  For each 129Xe/3He 
NDW and SV image, the VDV and the VV were normalized to the thoracic cavity 
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volume to get a ventilation defect percent (VDP) value and the percent ventilation 
volume (PVV) value respectively. 
For the 1H images, before applying the SRGA a two-dimensional radially 
symmetric Gaussian low-pass filter was applied to reduce the effects of intrapulmonary 
vasculature on the thoracic cavity segmentation.  A threshold based on the k-means 
algorithm was selected to convert the 1H images into a thoracic cavity binary mask.  
Following that, initial seed points were automatically selected in both the lungs by 
finding columns in the binary mask containing 20 vertically adjacent pixels below the 
threshold and the SRGA was used to generate the thoracic mask. 
For the registration process, a landmark-based affine transform consisting of 
rotation, translation and scaling operations was used to transform the 1H images to 
register them to the 129Xe/3He images.  Briefly, the center slices (defined as the slices that 
clearly showed the carina and primary bronchi) of the 1H and 129Xe/3He were first 
displayed side-by-side and the user was prompted to select 3-7 fiducial markers on both 
the slices.  Geometric operations consisting of rotation, scaling and translation were used 
to transform the 1H image to align it with the corresponding landmarks on the 129Xe/3He 
image.  The same transformation map was then applied to the rest of the slices to register 
all the 1H slices to the corresponding 129Xe/3He slices.   
The segmentation included manual steps to select the center slices for the proton 
and the 129Xe/3He images. The center slice was defines as the slice that clearly showed 
the trachea, carina and the main two bronchi. The other proton and 129Xe/3He slices were 
matched with each other depending on the center slices and the number of slices. The 
user also had to select the fiducial points for the registration step for registration of the 
proton and 129Xe/3He center slices. The same transformation was then applied to all the 
slices to register the proton slices to the 129Xe/3He slices. There was also a provision in 
the software for the user to manually include or exclude areas from the analysis 
depending on the anatomical information. The segmentation and the registration process 
is illustrated in Figure 2.4. 
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Figure 2.4 Schematic showing the semi-automated segmentation and registration process 
for 129Xe static ventilation and 1H images.   
Adapted from Kirby et.al.  (2012)6 
The signal-to-noise ratio (SNR) for all the 129Xe and 3He slices was determined by 
calculating the mean voxel signal value within a 5 x 5 cm2 voxel region of interest (ROI) 
for n representative ROIs inside the lung parenchyma, and dividing by the standard 
deviation of the voxel values for noise inside the same number of representative ROIs of 
the same dimensions in the image background where no lung structure was present.  The 
ROIs within the lung parenchyma and the image background were selected independently 
and randomly for each slice.   
2.5 Statistical Methods 
A repeated measures analysis of variance (ANOVA) was used to determine the 
main effects for repeated scans for VDP using IBM SPSS Statistics 20.0 (SPSS Inc., 
Chicago, IL, USA).  A two way mixed model intraclass correlation coefficient (ICC)9 
analysis under absolute agreement was used to determine the degree of agreement 
between different visits.  The ICC is a statistical analysis of agreement between two or 
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more measurements and the coefficient represents the agreement between those 
measurements.  Coefficient of variation (COV) analysis was included in the study to 
determine the variability between repeated scans and observers.  COV is a coefficient 
calculated as the standard deviation of the measurement as the percentage of its mean and 
lower COV values represent lower variability between measurements.  Linear regression 
(r2) and Pearson correlation coefficients (r) were used to determine the relationship 
between VDP values at different time-points, relationship between SNR and VDP, 
relationship between 2D and 3D image acquisition methods as well as the relationship 
between VDP and pulmonary function test measurements using GraphPad Prism version 
4.00 ( GraphPad Software Inc, San Diego, CA, USA).  In all statistical analyses, results 
were considered significant when the probability of making a Type I error was less than 
5% (p<.05).   
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3 CHAPTER 3: RESULTS 
This chapter describes the results of the analysis described in the previous 
chapter.  It describes the results of the reproducibility study for hyperpolarized 129Xe 
ventilation defect percent (VDP) measurement for same day rescan (scan and 2-minute 
rescan) as well as 1-week rescan (scan, 2-minute rescan and 1-week rescan) for healthy 
volunteers and COPD subjects for intra-observer and inter-observer reproducibility.  It 
also shows results for differences in VDP measurements for scans acquired using 2D and 
3D acquisition methods.  Also, we compare the reproducibility of 129Xe VDP to the 
reproducibility of 3He VDP.   
3.1 Subject Demographics  
Five healthy volunteers and ten COPD subjects (GOLD Stage I n=1; II n= 5; III 
n=3; IV n=1) were enrolled in the study.  Table 3.1 shows the subject demographics 
including the pulmonary function test results acquired at baseline (visit 1) for all the 
subjects.  No significant differences (p > 0.05) were observed between the healthy group 
and the COPD subjects for age or body mass index (BMI).  Significant differences were 
observed between the two groups for FEV1%pred (p < 0.001), FEV1/FVC (p < 0.001), TLC 
%pred (p < 0.01), RV%pred (p < 0.01), FRC%pred (p = 0.02) and DLCO %pred (p = 0.01) but not 
for FVC%pred (p = 0.2), RV/TLC (p = 0.06) and IC%pred (p = 0.14).  There were no 
significant differences in the FEV1 and FEV1/FVC values between the two visits for the 
three COPD subjects that returned for the 1-week rescan.  Three male HV and eight male 
COPD subjects were included in the study.   
One COPD subject had a mild adverse effect in the 24 hour period following the 
study visit, but was judged not related to the imaging procedure, the details of which are 
reported elsewhere.1  It resolved spontaneously, was asymptomatic (no clinical 
symptoms) and did not require withdrawal from the study.  There were no other scanning 
or breath-hold related adverse effects reported in the study.   
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Table 3.1 Subject Demographics 
Parameter Healthy  (n=5) 
COPD  
(n=10) P Value 
Age yrs (±SD) 68 (12) 74 (4) 0.18 
Male Sex n 3 8 - 
BMI kg·m-2 (±SD) 27 (2) 25 (5) 0.5 
FEV1 %pred (±SD) 105 (7) 57 (24) 0.001 
FVC %pred (±SD) 104 (8) 91 (19) 0.2 
FEV1/FVC (±SD) .75 (.02) .46 (.14) 0.001 
TLC %pred (±SD) 101 (7) 115 (8) 0.01 
RV%pred (±SD) 100 (9) 159 (46) 0.01 
RV/TLC (±SD) .38 (.08) .53 (.14) 0.06 
IC %pred (±SD) 108 (18) 85 (31) 0.14 
FRC%pred  (±SD) 95 (14) 141 (35) 0.02 
DLCO %pred (±SD) 99 (15) 54 (32)* 0.01 
SD=Standard Deviation, BMI=Body Mass Index, FEV1= Forced Expiratory Volume in 
1s, %pred=Percent Predicted, FVC= Forced Vital Capacity, TLC= Total Lung Capacity, 
RV= Reserve Volume, IC= Inspiratory Capacity, FRC= Functional Residual Capacity, 
DLCO=Carbon Monoxide Diffusion Capacity of the lung *n=9 (One subject was not able 
to complete the DLCO maneuver hence data available for nine of the ten subjects)  
 
3.2 129Xe MRI Baseline Measurements 
Figure 3.1 shows the center slice ventilation distribution for representative 
healthy volunteers and COPD subjects for 129Xe and 3He scans and the differences in 
ventilation observed using the two contrast agents.  Visually, elevated defects were 
observed for 129Xe MRI as compared to 3He MRI for the same subjects for scans acquired 
within a few minutes of each other.  Table 3.2 shows the average whole lung VDP values 
for the 15 subjects included in the study over the 5 rounds for hyperpolarized 129Xe and 
3He baseline NDW images for observer 1.  Quantitatively too, 129Xe VDP was 
consistently higher than 3He VDP for all the rounds which is consistent with previously 
reported observations.2  Figure 3.2 shows a bar graph with mean 129Xe VDP 
measurements for healthy volunteers and COPD subjects for each of the five rounds of 
VDP analysis for baseline NDW images.  Repeated measures ANOVA failed to show 
any significant differences in VDP measurements over the five rounds for healthy 
volunteers or COPD subjects. 
  
 
Figure 3.1 Non Diffusion Weighted (NDW) and static ventilation (SV) center slice images 
for 129Xe and 3He MRI for healthy volunteers and COPD subjects
Healthy subject S1 is a 26
is a 69 year old male (FEV
COPD subject S1 is a 77 year old female stage 3 COPD subject with FEV
FEV1/FVC = 50, S2 is a 79 year old male stage 2 COPD subject with FEV
FEV1/FVC = 36 
 
 
 
 
 year old female (FEV1%pred = 92% and FEV1/FVC = 0.91) 
1%pred = 101% and FEV1/FVC = 0.75) 
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Table 3.2 Mean values for VDP for a single observer for healthy volunteers and COPD 
subjects for 129Xe and 3He over 5 rounds of analysis of baseline NDW images 
 
 
 
The ventilation defects observed using hyperpolarized noble gases have previously been 
shown to be spatially related to pulmonary structural abnormalities, detected using CT 
and histology in COPD and lung cancer patients.3,4  This suggests that the abnormal 
ventilation pattern observed in COPD subjects using hyperpolarized noble gas imaging, is 
due to structural abnormalities in these subjects.   
 
129Xe MRI VDP (%) 
(n=15) 
3He MRI VDP (%) 
(n=15) 
Round 1  Mean (±SD) 26 (18) 16 (14) 
Round 2  Mean (±SD) 26 (17) 17 (14) 
Round 3  Mean (±SD) 27 (17) 17 (13) 
Round 4  Mean (±SD) 25 (18) 17 (14) 
Round 5  Mean (±SD) 25 (18) 17 (14) 
Figure 3.2 129Xe NDW VDP for Healthy Volunteers and COPD subjects 
Bar graphs showing mean 129Xe VDP for baseline NDW images for (A) Healthy 
volunteers (B) COPD subjects.  No significant differences (p > 0.05) were observed 
between the 5 rounds for healthy volunteers or COPD subjects.   
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We compared the 129Xe MRI VDP obtained from scans acquired using a 2D 
FGRE pulse sequence and a 3D FGRE pulse sequence for scans done within 10 minutes 
of each other for the same set of subjects.  We compared the VDP from NDW images 
obtained using a 2D FGRE sequence with VDP from SV images obtained with a 3D 
FGRE sequence.  Figure 3.3 shows the relationship of VDP from the NDW and the SV 
images.  A strong and significant correlation was obtained between the two time points 
and repeated measures ANOVA failed to show any significant difference between scans 
obtained using 2D and 3D pulse sequences (p = 0.496).  Intra-class correlation coefficient 
analysis showed significant and strong correlation between the 2D and 3D scans over 5 
rounds of analysis (ICC = 0.914) 
We also investigated the relationship between signal to noise ratio (SNR) and 
VDP to see if the differences in SNR between repeated scans were responsible for 
differences in VDP.  We found that there was no significant relationship observed 
between SNR and VDP (p = 0.95) for the 15 subjects.  Figure 3.4 shows the relationship 
for SNR and VDP. 
 
Figure 3.3 Relationship between pulse sequences for VDP 
Relationship between 2D and 3D acquisition methods for 129Xe MRI VDP. Solid line = 
mean difference, dashed line = 95% confidence intervals of regression line. 2D 
acquisition shows significant and positive correlation with 3D acquisition (r2 = 0.75,  
p < 0.0001; y = 0.97x + 2.17) 
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Figure 3.4 Relationship between 129Xe VDP and SNR 
Relationship between SNR and VDP for 129Xe MRI. Solid line = mean difference, dashed 
line = 95% confidence intervals of regression line. VDP shows no significant correlation 
with SNR (r2 = 0.00002, p = 0.95; y = 0.005x + 22.85) 
 
We analyzed the reproducibility of 129Xe MRI VDP measurements over short 
periods of time (same day rescan and 1-week rescan) when no pulmonary physiological 
changes were expected to occur in the subjects.  Two independent observers analyzed the 
NDW and SV images for VDP.  Observer 1 analyzed the 129Xe and 3He NDW and SV 
images 5 times (5 rounds) while observer 2 analyzed the 129Xe NDW images once (1 
round).  These data were then used to study the intra-observer and inter-observer 
reproducibility for 129Xe MRI VDP. 
3.3 Comparison of reproducibility of 129Xe MRI VDP and 3He MRI 
VDP  
Table 3.3 shows the repeated measures ANOVA p values for 129Xe MRI VDP 
and 3He MRI VDP for same day rescan for observer 1 over 5 rounds of VDP analysis.  
The p values failed to show any significant differences between the same day rescan for 
129Xe or 3He VDP.  The ANOVA also failed to show any significant difference between 
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the 5 rounds of VDP analysis for either contrast agent.  The interaction between the 
rounds and scans was also found to be not significant. 
Table 3.3 Repeated measures ANOVA for 129Xe VDP and 3He VDP for same day rescan 
Same-day = Same day rescan 
 
 
Table 3.4 shows ICC values for 129Xe VDP same day rescan as well as 3He MRI 
VDP same day rescan.  Both 129Xe MRI VDP and 3He MRI VDP showed strong and 
significant ICC values.  Table 3.4 also slows COV values for observer 1 and observer 2 
for 129Xe MRI VDP same day rescan and 3He MRI VDP for observer 1 for same day 
rescan for all the 15 healthy volunteers and COPD subjects.   
 
Table 3.4 ICC and COV analysis for 129Xe MRI VDP and 3He MRI VDP for same day 
rescan 
Same-day = Same day rescan 
  
 
129Xe MRI (P value) 3He MRI (P Value) 
 Same-day (n=15) Same-day (n=15) 
Rounds 0.162 0.105 
Scans 0.878 0.138 
Rounds * Scans 0.404 0.108 
 
129Xe MRI  3He MRI  
 Same-day (n=15) Same-day (n=15) 
ICC 0.949 (<.0001) 0.962 (<.0001) 
COV (Obs 1) (%) 11 14 
COV (Obs 2) (%) 10 - 
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3.4 129Xe MRI Intra-Observer Reproducibility 
Figure 3.5 shows the ventilation distribution for 129Xe NDW scans for three 
COPD subjects who had two NDW scans at visit 1 (baseline scan, 2-minute rescan) and 
repeated NDW scans (scan, 2-minute rescan) one week later.  The center slices for the 
NDW 129Xe MRI scans are shown in the figure for baseline scan, same day rescan and 1- 
week rescan.  The ventilation distribution is highly heterogeneous for these COPD 
subjects and the location of defects is visually consistent over the three time points.  The 
three subjects showed no significant differences in spirometry (FEV1, FVC or 
FEV1/FVC) between the two visits separated by a period of 1 week.  The repeated NDW 
scans were used to access the reproducibility of hyperpolarized 129Xe MRI VDP.  Data 
from the 15 subjects who had the scan and 2-minute rescan were used to study the same 
day reproducibility of 129Xe VDP while data from the three COPD subjects who had the 
scan, 2-minute rescan and 1-week rescan were used to study the 1 week reproducibility.   
  
 
Figure 3.5 129Xe NDW images over three time points for three COPD subjects
Subject S1 is a 79 year old male stage 2 subject with FEV
Subject S2 is a 76 year old male stage 2 subject with FEV
Subject S3 is a 73 year old male stage 4 subject with FEV
Same day = Same day rescan, 1 Week = 1
 
 
 
1%pred = 52 and FEV
1%pred = 77 and FEV
1%pred = 26 and FEV
-week rescan 
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1/FVC = 36 
1/FVC = 54 
1/FVC = 29 
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Table 3.5 shows repeated measures ANOVA P values for 129Xe VDP for same 
day reproducibility (baseline NDW scan, 2-minute NDW rescan) for 15 subjects.  It also 
shows results for 1-week reproducibility (baseline NDW scan, 2-minute NDW rescan and 
1-week NDW rescan) for 3 subjects.  The table shows the main effects for 5 rounds of 
VDP analysis by observer 1 and the main effects for repeated scans, as well as the 
interaction between the 5 rounds and scans.  The ANOVA failed to show any significant 
main effects for the 5 repeated rounds of VDP analysis or the repeated scans of 129Xe 
MRI.  The interaction between the rounds and the scans was also not significant for 
same-day rescan or 1-week rescan.   
Table 3.5 Repeated measures ANOVA for intra-observer reproducibility: 129Xe VDP 
same day rescan and 1-week rescan 
 
129Xe MRI (P value) 
 Same-day (n=15) 1-Week (n=3) 
Rounds 0.162 0.284 
Scans 0.878 0.127 
Rounds * Scans 0.404 0.315 
Same-day = Same day rescan, 1-Week = 1-week rescan 
ICC analysis for the repeated 129Xe scans is shown in Table 3.6.  Strong and 
significant ICC values were observed for all the 129Xe repeated scans.  The 1-week rescan 
showed a slightly weaker correlation compared to the same day rescan although the 
correlation was significant and strong (ICC = 0.861).  The COV analysis for 129Xe VDP 
for the same day rescan for observer 1 and observer 2 is shown in Table 3.6.  The table 
also shows the COV analysis for the 1-week rescan for both the observers.   
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Table 3.6 ICC and COV Analysis for intra-observer reproducibility: 129Xe VDP same day 
rescan and 1-week rescan 
ICC = Intra class correlation coefficient, COV = Coefficient of Variation.  Numbers in 
parentheses are P values, Obs 1= Observer 1, Obs 2= Observer 2 
Same day = Same day rescan, 1-Week = 1-week rescan 
 
Figure 3.6 shows relationship for 129Xe NDW scans over multiple time points.  It 
shows the correlation for the baseline scan VDP with the same day rescan VDP for 
observer 1 over 5 rounds.  Strong and significant correlation was observed for this 
comparison.  It also shows the correlation for the baseline NDW scans with the NDW 
scans obtained one week later for three COPD subjects.  For this comparison too, strong 
and significant correlation was observed.   
Figure 3.6 Relationship between repeated scans for VDP 
Relationship between same day and 1-week repeated scans for 129Xe MRI VDP. Solid 
line = mean difference, dashed line = 95% confidence intervals of regression line.  
A) Significant and strong correlation between scan and same-day rescan (r2 = 0.83,  
p < 0.0001; y = 0.87x + 2.03), B) Significant and strong correlation between scan and 1-
week rescan (r2 = 0.83, p < 0.0001; y = 1.01x + 6.22) 
 
129Xe MRI  
 Same-day (n=15) 1-Week (n=3) 
ICC 0.949 (<.0001) 0.861 (<.0001) 
COV (Obs 1) (%) 11 13 
COV (Obs 2) (%) 10 13 
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3.5 129Xe MRI Inter-Observer Reproducibility 
To evaluate the inter-observer reproducibility for hyperpolarized 129Xe MRI VDP, 
a second observer analyzed the repeated 129Xe NDW MR images for VDP.  Repeated 
measures ANOVA failed to show significant differences between the two observers or 
between repeated scans for the same day rescan or the 1-week rescan as shown by the 
non significant p values in Table 3.7.  The interaction between the observers and the 
scans was also not significant for same day rescan or the 1-week rescan. 
Table 3.7 Repeated Measures ANOVA for inter-observer reproducibility: 129Xe VDP 
same day rescan and 1-week rescan 
 Same-day = Same day rescan, 1-Week = 1-week rescan  
Table 3.8 shows the ICC and COV values for inter-observer reproducibility 
analysis for two observers for repeated scans for same day rescan and 1-week rescan.  
Significant and high ICC values were observed for both the comparisons. 
Table 3.8 ICC and COV for inter-observer reproducibility: 129Xe VDP same day rescan 
and 1-week rescan 
ICC = Intraclass correlation coefficient, COV = Coefficient of Variation.  Numbers in 
parentheses are P values.  Same day = Same day rescan, 1-Week = 1-Week rescan 
 
 
129Xe MRI (P value) 
 Same-day (n=15) 1-Week (n=3) 
Observers 0.550 0.205 
Scans 0.877 0.143 
Observers * Scans 0.823 0.368 
 
129Xe MRI  
 Same-day (n=15) 1-Week (n=3) 
ICC 0.978 (< .0001) 0.929 (< .0001) 
COV (%) 11 11 
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Figure 3.7 shows the inter-observer relationships for same day rescan for 129Xe 
VDP as well as the 1-week rescan for 129Xe VDP.  Significant and strong correlations 
were observed for both the comparisons.   
Figure 3.7 Inter-observer correlations for 129Xe VDP 
Obs 1 = Observer 1, Obs 2= Observer 2 
Relationship between VDP analysis by two observers for 129Xe MRI. Solid line = mean 
difference, dashed line = 95% confidence intervals of regression line. A) Significant and 
strong correlation between observers for same-day rescan (r2 = 0.98, p < 0.0001;  
y = 0.91x + 2.02), B) Significant and strong correlation between observers for 1-week 
rescan (r2 = 0.99, p < 0.0001; y = 0.97x + 1.40) 
 
 
3.6 129Xe MRI VDP relationship to pulmonary function 
measurements  
Significant and strong correlations were observed between baseline NDW 129Xe 
VDP values and the gold standard measurements for obstructive lung disease diagnosis-
FEV1%pred and FEV1/FVC as shown in Figure 3.8.  Significant and moderate to strong 
correlations were also observed between VDP and lung volume measurements like RV 
(r2 = 0.91), RV/TLC (r2 = 0.55) and FRC (r2 = 0.80).  A significant and strong 
relationship was also observed between VDP and DLco (r2 = 0.74).  Significant and 
moderate correlations were observed between VDP and TLC (r2 = 0.59) and IC (r2 = 
0.52) but not with FVC (r2 = 0.23, p = 0.07). 
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Figure 3.8 129Xe baseline NDW VDP correlations with pulmonary function tests 
Relationship between VDP and PFT measurements for all 15 subjects. Solid line = mean 
difference, dashed line = 95% confidence intervals of regression line. A) Significant and strong 
correlation between VDP and FEV1 (% pred) (r2 = 0.80, p < 0.0001; y = -0.50x + 64.9),  
B) Significant and strong correlation between VDP and FEV1/FVC (r2 = 0.91, p < 0.0001;  
y = -0.89x + 77.57), C) Significant and strong correlation between VDP and RV (r2 = 0.71, 
 p < 0.0001; y = 0.31x -14.92), D) Significant and moderate correlation between VDP and  
RV /TLC (r2 = 0.55, p = 0.0015; y = 0.92x -16.01), E) Significant and strong correlation 
between VDP and FRC (r2 = 0.80, p < 0.0001; y = 0.42x -24.72), F) Significant and strong 
correlation between VDP and DLCO (r2 = 0.74, p < 0.0001; y = -0.42x + 56.58),  
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4 CHAPTER 4: DISCUSSION AND FUTURE WORK 
In this final chapter, I will highlight all the important findings from this 
reproducibility study of hyperpolarized 129Xe MRI VDP measurement.  A discussion of 
the relevance of this work is presented based on the results from Chapter 3.  Finally, the 
limitations of the study are presented followed by the future directions for this work and 
the conclusion for this study. 
To our knowledge, this is the first study that looks at the reproducibility of 
hyperpolarized 129Xe MRI VDP.  We report: 1) No significant differences in VDP for 
scans acquired using a 2D FGRE pulse sequence compared to scans acquired using a 3D 
FGRE pulse sequence, 2) No correlation between SNR and VDP for 129Xe MRI, 3) 
Visual and quantitative evidence of elevated defects using 129Xe as a contrast agent 
compared to 3He, 4) High intra-observer reproducibility for 129Xe VDP and 3He VDP for 
same day rescan, 5) High intra-observer reproducibility for 129Xe VDP for same day and 
1-week rescan, 6) High inter-observer reproducibility for 129Xe VDP for same day and 1-
week rescan, 7) Significant and strong correlation between 129Xe VDP and pulmonary 
function test measurements. 
4.1 129Xe MRI Baseline Measurements 
For the 129Xe MRI scans, I compared the VDP obtained using a 2D FGRE pulse 
sequence with the VDP obtained using a 3D FGRE pulse sequence, for the same subjects 
for scans acquired within a few minutes of each other.  NDW images acquired using a 2D 
FGRE sequence were compared with SV images acquired using a 3D FGRE sequence.  
The major difference between the 2D and the 3D FGRE pulse sequence was that in the 
3D acquisition, magnetic resonance data was acquired from a volume rather than a single 
tomographic slice.  An additional phase encode pulse was applied in the 3D acquisition to 
image a greater thickness of tissue compared to the 2D acquisition.  Repeated measures 
ANOVA failed to show any significant differences for 129Xe VDP between 2D FGRE 
and 3D FGRE scans acquired within a few minutes of each other.  Significant and strong 
ICC values were observed for the comparison of 5 rounds of NDW and SV image 
analysis.  The ICC is a statistical analysis of agreement between two measurements, and 
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the coefficient represents the agreement in VDP values for observer 1 between the 2D 
acquisition and the 3D acquisition for same day rescan.  A strong ICC value, as was 
observed for the NDW scan and SV same day rescan for 129Xe VDP, represents a good 
agreement between the VDP values obtained at the two time-points using the two 
different pulse sequences.  A significant and strong correlation was also observed 
between the VDP values for scans acquired using the two image acquisition methods.  3D 
acquisition typically provides a better SNR for imaging lung ventilation with 
hyperpolarized noble gases as well as better spatial resolution.1  Therefore, 3D sequences 
will be useful for studies that need to accurately calculate the ventilation volume and 
ventilation defect volume which requires high spatial resolution in all three dimensions.   
I also investigated the relationship between SNR and VDP for 129Xe MRI, to see 
if the differences in SNR between repeated scans were responsible for differences in 
VDP values.  It is important to investigate this relationship because typically 129Xe MRI 
images are of a lower SNR than 3He images due to the differences in the physical 
properties between the two gases.  Also, repeated scans using the same contrast agent can 
have large variations in SNR depending on the imaging procedure used, including the 
scanner and pulse sequence, polarization of the gas itself and the breath-hold maneuver 
performed by the subject.  We found that there was no significant relationship observed 
between SNR and VDP (p = 0.95) for the 15 subjects included in the study.  These results 
suggest that the differences in SNR between repeated scans were not responsible for 
differences in VDP values.  This is an important observation since SNR values can vary 
to a great degree and the reproducibility of the VDP measurement would be affected if 
SNR had an effect on the VDP measurement.   
4.2 Comparison of reproducibility of 129Xe MRI VDP and 3He MRI 
VDP 
We compared the reproducibility of hyperpolarized 129Xe MRI VDP with the 
reproducibility of 3He MRI VDP.  First, both visually and quantitatively, 129Xe MRI 
showed elevated defects as compared to 3He MRI for the same set of subjects for scans 
acquired within 10 minutes of each other, which is consistent with previously reported 
observations.2,3  The differences in the physical properties of 129Xe and 3He may provide 
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an explanation for this observation.  Kirby et al. reported that the lower diffusion 
coefficient of 129Xe compared to 3He may be responsible for slower filling of 129Xe  in the 
diseased lung regions, leading to elevated defects observed in 129Xe MRI.2  Previous 
studies have reported that 3He MRI measurements are reproducible over short periods of 
time in healthy volunteers and subjects with obstructive lung disease.4-8  It is important to 
study if the differences in the physical properties of the two gases are reflected as 
differences in the reproducibility of 129Xe MRI VDP compared to the reproducibility of 
3He MRI VDP. 
For the same set of subjects, repeated measures ANOVA failed to show any 
significant differences in VDP values for repeated 129Xe MRI scans as well as 3He MRI 
scans for same day rescan (scans acquired on the same day within 2 ± 1 minutes of each 
other).  There were no significant differences in the 5 rounds of repeated VDP analysis 
for 129Xe or 3He MRI indicating good intra-observer reproducibility for same day rescan 
for 129Xe and 3He VDP.  Significant and strong ICC values were observed for same day 
rescan for both 129Xe VDP and 3He VDP.  The ICC is a statistical analysis of agreement 
between two measurements, and the coefficient represents the agreement in VDP values 
for observer 1 between the scan and the same day rescan.  A strong ICC value, as was 
observed for the scan and the same day rescan for both 129Xe and 3He, represents a good 
agreement between the VDP values obtained at the two time-points for both the contrast 
agents.  The COV values for observer 1 and observer 2 were 11% and 10% respectively 
for 129Xe VDP, and that for 3He was 14% for observer 1.  Observer 2 did not analyze the 
3He images and hence a COV value for observer 2 was not available.  COV is a 
measurement of the standard deviation as a percentage of the mean and lower COV 
values for 129Xe VDP compared to 3He VDP suggest that there is lower variation in 129Xe 
VDP same day rescan compared to 3He VDP same day rescan.  However, this 
interpretation should be made with caution using COV analysis as there are major 
limitations for this statistical method.  For one, COV is the ratio of standard deviation 
over mean.  The mean values for VDP were observed to be significantly lower for 3He 
compared to 129Xe and hence the COV might not accurately reflect the difference in 
variation between the two contrast agents.  Secondly, our subject cohort included healthy 
volunteers who have low mean VDP values and hence push the COV values up.  All 
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factors considered, this analysis suggests that the intra-observer reproducibility of 129Xe 
MRI VDP and 3He MRI VDP is high for same day rescan for healthy volunteers and 
subjects with COPD. 
4.3 129Xe MRI Intra-Observer Reproducibility 
We analyzed the intra-observer reproducibility of 129Xe VDP for same day rescan 
(scan, 2- minute rescan) and 1-week rescan (scan, 2-minute rescan and 1 week rescan) for 
5 rounds of VDP analysis.  For the same day rescan, a repeated measures ANOVA failed 
to show any  significant differences between the VDP values for repeated scans for the 
cohort of 15 subjects, which included healthy and COPD subjects.  There are several 
sources of variation for scans acquired within 2 minutes of each other, such as 1) subject 
compliance (breath-hold, motion), 2) polarization of the gas and gas delivery methods, 3) 
observer dependence in the semi-automated segmentation software.  We tried to 
minimize the variation in repeat scans due to subject compliance by giving the subjects 
extensive coaching regarding inhalation of the contrast agent and the breath-hold 
requirements.  The observer variation in the segmentation and registration steps was 
minimized by giving the observers extensive training regarding the use of the semi-
automated segmentation software.  These results suggest that the 129Xe VDP 
measurement is robust to variations between scans acquired over short periods of time.  
The ANOVA also failed to show any significant difference between the 5 rounds of VDP 
analysis for the single observer for same day rescan.  This suggests high intra-observer 
reproducibility for the VDP measurement for same day rescan of 129Xe MRI.  The ICC 
value for same day rescan for 129Xe VDP was significant and strong indicating good 
agreement between the VDP values for the repeated scans.  The COV values for same 
day rescan were 11% and 10% for the two observers.  The COV values were higher than 
previously reported COV values for 3He VDV for COPD subjects.9  However, this 
subject cohort included healthy subjects along with COPD subjects, who on account of 
their lower mean VDP values push the COV values higher.  The COV values observed 
for 129Xe VDP for same day rescan were lower than those for 3He VDP same day rescan 
for the same subject cohort.  These results suggest that 129Xe MRI VDP is highly 
reproducible for same day rescan when no physiological pulmonary changes are expected 
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to occur.  The measurement is robust to variations in subject compliance, polarization of 
the gas as well as the observer error in the semi-automated segmentation method for 
scans acquired within a few minutes of each other.   
For the 1-week rescan reproducibility, the ANOVA failed to show any significant 
differences between the scan, 2 minute rescan and 1-week rescan for the three COPD 
subjects that had the 1-week repeat scan.  Visually too, the defects appeared consistent 
over the three repeated scans.  There are several sources of variation for scans acquired 1-
week from each other, such as 1) subject compliance (breath-hold, motion), 2) 
polarization of the gas and gas delivery methods, 3) scanner 4) position of the coil within 
the bore of the MRI 5) observer dependence in the semi-automated segmentation 
software, 6) potential physiological changes.  An effort was made to keep the variation in 
the position of the coil inside the bore of the scanner to a minimum between the scans.  
The three COPD subjects showed no significant differences in spirometry (FEV1, FVC or 
FEV1/FVC) between the two visits separated by a period of 1-week suggesting that no 
significant global change in respiratory function had taken place over the one week 
period.  These results suggest that the 129Xe MRI VDP measurement is robust to 
variations in scans over a period of one week.  This implies that the 129Xe MRI VDP 
measurement is reproducible over longer periods of time and can cope with variations 
arising from various sources like the patient, scanner, contrast agent as well as the 
observer analyzing the images.  The repeated measures ANOVA failed to show any 
significant differences in the 5 repeated rounds of VDP analysis for the 1-week rescan.  
This suggests that 129Xe MRI VDP shows good intra-observer reproducibility for 1-week 
repeated scan.  Significant and strong ICC values were observed for the 1-week rescan 
for 129Xe VDP indicating good agreement between the VDP values for the three repeated 
scans.  The COV for the 1 week rescan was 13% for both the observers who analyzed the 
129Xe repeated scans.  Significant and strong correlation values were observed for same 
day rescan and 1-week rescan. 
In order to be confident about the physiological changes and biological 
phenomenon observed in the subject, we should be confident that the source of the 
variation in the measurement is from the subject (physiological change) and not from any 
stage of the imaging procedure.  The results for the intra-observer reproducibility suggest 
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that 129Xe MRI VDP is a highly reproducible measurement over same day rescans as well 
as over 1-week rescans and can be used as a reliable measurement for pulmonary imaging 
studies.   
4.4 129Xe MRI Inter-Observer Reproducibility 
Two independent observers analyzed the 129Xe same day and 1-week repeated 
scans for evaluation of inter-observer reproducibility of VDP measurement.  For the same 
day rescan, a repeated measures ANOVA failed to show any significant differences in 
VDP measurement between the two observers.  Also, the ANOVA failed to show any 
significant differences between the repeated scans for the same day rescan for either 
observer.  For the 1-week rescan too, it failed to show any significant differences in VDP 
between the two observers.  As well as the scan, the same day rescan and the 1-week 
rescan.  The segmentation software used for the calculation of VDP is semi-automated 
with the observer providing input regarding which areas of the lung are classified as 
defects and also has to select fiducials for the registration step.  These results suggest that 
the inter-observer variability in this process is not significant between observers and 
different observers analyze the images in a consistent way, when properly trained to use 
the software.  This suggests that the VDP measurement can be reliably used in multi-
observer or even multi-center research studies if the observers are properly trained.  The 
ICC value showed a significant and strong agreement between the two observers for the 
scan and same day scan as well as the scan, same day rescan and 1-week rescan.  The 
COV was observed to be 11% between the two observers for both the scan and same day 
rescan as well as the scan, same day rescan and 1-week rescan.  Although this COV value 
seems high, it has to be considered that the subject cohort contains healthy volunteers 
who push the COV value up because of their low mean VDP.  The correlation coefficient 
between the two observers for VDP measurement was found to be significant and strong 
for the scan and same day rescan and the scan, same day rescan and 1-week rescan.  
These results suggest that the inter-observer reproducibility for 129Xe VDP is high and the 
measurement can be reliably used in multi-observer and multi-center studies.   
85 
 
 
 
4.5 129Xe MRI VDP relationship to Pulmonary Function 
Measurements 
We evaluated the relationship between VDP and all the pulmonary function test 
measurements.  There was a strong and significant inverse correlation between VDP and 
the gold standard measurement for obstructive lung disease diagnosis – FEV1/FVC.  
Significant and strong inverse correlation was also observed between VDP and FEV1%pred 
but a significant relationship was not observed between VDP and FVC% pred.  Subjects 
with obstructive lung disease have a reduced FEV1/FVC ratio because of airway 
narrowing caused by a lot of factors including thickening and obliteration of airways and 
small airways disease.  FEV1/FVC reduction in obstructive lung disease has been 
reported to be sensitive to airway narrowing and bronchoconstriction.10  The significant 
and strong correlation of VDP with FEV1/FVC suggests that VDP can be a very useful 
tool for studying the different airway and parenchymal abnormalities in obstructive lung 
disease.  FEV1%pred value is used for the classification of COPD subjects into different 
stages, depending on the severity of the disease.11
 
 A significant and strong correlation 
between 129Xe VDP and FEV1%pred suggests that VDP can be used to classify subjects into 
stages depending on the ventilation abnormalities and VDP values.  Similar relationships 
between ventilation defects and spirometric measurements have been previously reported 
in obstructive lung disease using 3He and 129Xe MRI measurments.2,12,13 We also 
observed a significant and strong positive correlation between 129Xe VDP and RV.  In 
COPD patients, the RV values increases markedly due to “gas trapping” in the alveoli.  
Gas trapping is caused by the decrease in the elastic recoil of the lungs due to fibrosis as 
well as the collapse of the bronchioles during expiration leading to large amounts of air 
being trapped in the alveoli.  The significant and strong correlation between 129Xe VDP 
and RV suggests that VDP might be a good tool for diagnosis of gas trapping in patients 
suffering from COPD.  There was also a significant and strong inverse correlation 
between VDP and DLCO observed.  DLCO is a surrogate measurement for the diffusion of 
oxygen across the alveolar membrane into the blood.  The strong correlation suggests that 
VDP might be a good indicator of emphysema in subjects suffering from COPD.  The 
strong correlations observed between 129Xe MRI VDP and the pulmonary function test 
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measurements suggest that VDP might be a useful tool for obstructive lung disease 
diagnosis, monitoring disease progression and evaluating response to treatment. 
4.6 Study Limitations 
We acknowledge that this work was limited due to the small number of subjects 
included in the study, especially for the 1-week rescan.  Since we had a small subject 
size, caution should be exercised when extrapolating these results to the general COPD 
population and other obstructive and restrictive lung disease populations.  We did not 
evaluate the reproducibility of 129Xe MRI VDP in other obstructive and restrictive lung 
diseases other than COPD.  For the COPD subjects who returned for the 1-week rescan, 
we did not acquire proton scans at the 1-week rescan and had to use proton scans from 
the baseline visit.  Although the shape and size of the thoracic cavity is not expected to 
change significantly over a one week period, this could potentially be a source of error 
for the 1-week rescan VDP.    Another limitation of the study is that we did not acquire 
repeated 3He MRI scans for 1-week rescan for the three COPD subjects and hence a 
direct comparison between 129Xe VDP and 3He VDP for 1-week rescan reproducibility 
could not be made. 
4.7 Future Work 
The results and discussions presented in this thesis provide some important 
insights in the intra-observer and inter-observer reproducibility of hyperpolarized 129Xe 
MRI VDP measurement and provide the foundation for future work.  The reproducibility 
of 129Xe VDP measurement needs to be evaluated in other pulmonary diseases like 
asthma, CF and RILI.  The reproducibility of 129Xe MRI ADC measurement, used to 
probe the lung microstructure, needs to be evaluated for obstructive and restrictive lung 
diseases. 
Over the last two decades, there has been tremendous progress made in 
understanding structural and functional changes in pulmonary diseases using 
hyperpolarized 3He MRI.  However, due to the limited availability and high cost of 3He, 
its clinical translation has not been possible.  129Xe is more abundant and cheaper and 
hence is a much more realistic option as a contrast agent in clinical applications.  
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However, due to the differences in the physical properties between 129Xe and 3He, many 
of the studies and work performed using 3He will have to be reproduced using 129Xe.  
While recently there have been studies performed comparing 129Xe and 3He MRI 
measurements in healthy volunteers and subjects with pulmonary diseases,2,3,14 there is a 
need to perform more studies using 129Xe MRI probing the effects of the differences in 
the physical properties of 129Xe in comparison to 3He on pulmonary imaging 
measurements. 
4.8 Conclusion 
The development of pulmonary imaging techniques has led to advancements in 
our understanding of pulmonary structural and functional changes associated with 
pulmonary disease.  Spirometry and plethysmography, which provide gold standards 
measurements for obstructive lung disease diagnosis, are limited because they provide 
only a global measurement of lung function in regionally highly heterogeneous diseases 
like COPD and asthma and are insensitive to early stages of the disease.  CT, the gold 
standard for pulmonary lung structure evaluation, is limited by its high radiation dose and 
its inability to provide regional functional information in pulmonary disease.  
Hyperpolarized noble gas magnetic resonance imaging (MRI) has emerged as a non-
invasive, non-radiation based sensitive tool for visualizing the regional lung structure and 
function.  129Xe is one of the contrast agents that can be used for hyperpolarized gas 
pulmonary imaging.  However, the reproducibility of hyperpolarized 129Xe MRI 
measurements had not yet been studied or determined.  Hence, the aim of this thesis was 
to evaluate the reproducibility of hyperpolarized 129Xe MRI measurements over short 
periods of time.  Our results show that hyperpolarized 129Xe MRI VDP has high intra-
observer and inter-observer reproducibility for scans acquired on the same day as well as 
after a period of 1-week.  129Xe MRI VDP also showed strong and significant correlations 
with pulmonary function test measurements.  These results suggest that hyperpolarized 
129Xe MRI VDP is reproducible over short periods of time and can be used as a reliable 
measurement to study pulmonary function in imaging studies.  Hyperpolarized 129Xe 
MRI is able to provide pulmonary structural and functional information and has emerged 
as a very important tool in pulmonary imaging research studies.   
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